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ABSTRACT 
The bone marrow (BM) is the main site of hematopoiesis in mammals and it is here that 
hematopoietic stem and progenitor cells proliferate and differentiate to produce all the 
mature cells of the blood. The BM also contains several non-hematopoietic stromal 
populations and these, along with hematopoietic cells and signals emanating from outside 
the bone marrow, communicate to regulate the production of mature cells. In this thesis I 
describe two novel aspects of this intricate regulation: 1) granulocytes crosstalk with BM 
endothelial cells to promote regeneration following bone marrow injury; and 2) neonatal 
gut microbes can regulate the proliferation and lineage commitment of hematopoietic 
stem cells (HSCs) in the BM via long distance communication. 
Previous studies demonstrated that vascular regeneration was a necessary precedent for 
the restoration of functional hematopoiesis following BM injury. While studying the 
mechanisms that regulate vascular recovery, we discovered that adoptive transfer of 
granulocytes into recipients undergoing bone marrow transplant (BMT) led to increased 
recovery and function of the BM vasculature, faster recovery of hematopoietic cells in the 
peripheral blood, and overall increased survival of transplant recipients. A screen of BM 
granulocytes for angiogenic factors identified TNFα as a potential candidate for the 
regenerative phenotype. Genetic studies using Tnfα-/- granulocytes and TNFα receptor
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null recipients validated granulocyte-derived TNFα as a newly discovered regulator of
vascular regeneration.  
Concurrent to this research we also discovered a new role for the gut microbiota in 
regulating hematopoiesis. We discovered this by initially testing whether neonatal 
microbes could expand granulocyte numbers in the BM; as a connection between gut 
microbes during neonatal development and the expansion of BM granulocytes had been 
previously described. Surprisingly, we did not observe any difference in granulocyte 
numbers when comparing germ-free and specific pathogen free (SPF) neonates. 
However, when analyzing the function of the HSCs in these two groups, we found reduced 
proliferation and increased production of myeloid and T-cells in SPF neonates when 
compared to their germ-free counterparts. When germ-free neonates were fostered with 
a SPF dam or when neonatal (but not adult) gut microbiota were adoptively transferred 
into adult germ-free recipients, these same HSC phenotypes were observed, suggesting 
that manipulation of the composition of the gut microbiota is capable of influencing 
hematopoiesis in the BM at all stages of development. Taking both of these projects 
together, these results reveal that granulocytes and gut microbes can regulate 
hematopoiesis during homeostasis and regeneration. 
CHAPTER ONE: 
INTRODUCTION 
Blood cell production takes place in the bone marrow space where a complex network of 
hematopoietic and non-hematopoietic stromal cells interacts to form the bone marrow 
microenvironment. These cells form a unique three-dimensional structure to allow for the direct 
communication that are necessary for maintaining and regulating differentiating hematopoietic 
cells. In particular, this interaction of the microenvironment is essential for the proper 
maintenance of the hematopoietic stem cell (HSC). Years of research have allowed for the 
identification of several hematopoietic and stromal cells that are critical for HSC regulation and 
have come to be known as the HSC niche. More specifically, these HSC niche cells have been 
shown to produce cytokines necessary for regulating HSC numbers, as well as, trafficking to 
and from the bone marrow, self-renewal, differentiation, and proliferation (1-7). 
THE HSC NICHE 
Within the stromal compartment of the bone marrow, several cells have been validated as 
components of the HSC niche. One of the first populations identified were the endothelial cells 
that comprise all of the bone marrow vasculature, both sinusoidal and arteriolar blood vessels. 
These blood vessels are in turn almost completely ensheathed in two distinct populations of 
stromal perivascular cells; called the LepR+ (also Nestindim (8-11) or CD45-TER119-CD31-
CD51+CD140α+ (12)) and the Ng2+ (also called Nestinbright (8)) perivascular populations. LepR+
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cells are found in contact with all bone marrow endothelium, while Ng2+ cells are much rarer 
and found only in contact with bone marrow arterioles. Using the LepR and Ng2 promoters for 
specificity, researchers have analyzed loss-of-function models to determine the involvement of 
these perivascular cells on HSC function. LepR+- and Ng2+-specific deletion of the critical HSC 
maintenance factors, CXCL12 and SCF, leads to severe loss of HSCs from the bone marrow 
and dramatically impaired hematopoiesis (10-11, 13).  This close association to the vasculature 
is not unique, however. In fact, several other HSC niche components are also found in very close 
proximity to the blood vessels. The sympathetic nervous system innervates the bone marrow 
cavity and these axons follow along the vascular network. Lack of norepinephrine signaling from 
these bone marrow neurons leads to increased mobilization of HSCs into the peripheral blood 
and ultimately, loss of HSCs from the bone marrow (14-15). 
Interestingly, mature hematopoietic cells have also been identified as HSC niche components. 
The Megakaryocyte is a large, multinucleated blood cell that is found in very close proximity to 
bone marrow sinusoids where they produce platelets. Depletion of Megakaryocytes or loss of 
HSC regulatory signals from these cells does not lead to immediate loss of the associated HSCs. 
Instead, the percent of proliferating HSCs increases and HSCs relocate farther away from the 
vasculature. Overtime, with continued loss of these signals, the HSC pool becomes less 
quiescent and eventually exhausts (16-19).  Not all HSC niche components directly regulate the 
HSC pool in the bone marrow. The CD169+ bone marrow macrophage has also been shown to 
be important for regulating expression of critical HSC regulatory cytokines, like CXCL12, on the 
LepR+ perivascular population through clearance of aged neutrophils (20-22).  Taken all 
together, this research shows the existence of a perivascular niche for HSCs and that these 
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multi-cellular structures work together to produce the factors necessary to promote HSC 
maintenance and function (Figure 1).
THE BONE MARROW VASCULATURE AS A KEY COMPONENT OF THE HSC 
NICHE 
As every known HSC niche resides next to the bone marrow vasculature, this places the 
endothelial cells as a key constituent. The bone marrow is heavily vascularized to supply the 
cavity with oxygen and nutrients necessary for the constant production of blood cells. Arteries 
penetrate the bone marrow space where they branch off into smaller arterioles. These arterioles 
traverse along the endosteum – the small layer between bone marrow and bone surface – where 
they flow into venous sinusoids. These sinusoids make up the bulk of the complex vascular 
network and it is these vessels that serve as a means of egress for mature hematopoietic cells 
entering circulation. While initial studies using fluorescently labeled hematopoietic progenitors 
transplanted into irradiated recipient mice suggested that hematopoietic stem and progenitor 
cells (HSPCs) localize in the endosteal region of the bone marrow (23), more recent analyses 
have shown that immunophenotypically-defined HSCs actually reside in very close proximity to 
the bone marrow vasculature (24). In fact, almost all HSCs in the bone marrow can be found 
within 5 µm of the blood vessels (8, 10-11, 24-25). Endothelial cells also produce a wide range 
of angiocrine factors, chemokines, and extracellular matrix components like CXCL12 (10-11, 26-
30), SCF (10-11, 31), Pletiotrophin (32-33), and Notch ligands (34-35) and have been shown to 
support long-term HSC function in culture (36-39). While this data heavily suggested the 
existence of a perivascular HSC niche, the ability to validate the vasculature as a niche 
component has been challenging as the genetic or chemical depletion of bone marrow 
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endothelial cells are not compatible with life. Using vascular-specific Cre mouse lines, 
researchers were able to test the importance of endothelial cells as a source of HSC regulatory 
factors. Scfgfp and Cxcl12-DsRed reporter mice revealed that endothelial cells were a major
contributor of these two proteins – along with LepR+ perivascular cells (10-11). While 
hematopoietic cells were negative for GFP, some hematopoietic cells showed expression of the 
DsRed reporter. Using the hematopoietic-specific reporter Vav1-Cre, researchers deleted SCF
(Vav1-Cre;Scffl/- (10)) and CXCL12 (Vav1-Cre;Cxcl12fl/fl (11)) from the hematopoietic
compartment and found absolutely no change to the hematopoietic system. However, when 
researchers used the Tie2 promoter (which targets hematopoietic and endothelial cells) to delete 
SCF and CXCL12, a robust phenotype was observed. Conditional deletion of SCF using the 
Tie2-Cre:Scf fl/- mouse model, resulted in severe depletion of HSCs in the bone marrow during
steady-state and significant impairment in reconstitution of the hematopoietic system following 
competitive transplantation (10). Additionally, analysis of the Tie2-Cre:Cxcl12fl/fl mouse model
also exhibited severe loss of HSCs from the bone marrow along with impaired reconstitution in 
a competitive transplant (11, 29-30). 
Using the TNR.Gfp reporter mouse (which induces expression of Gfp upon Notch activation),
researchers were able to identify endothelial cells as a source of Notch ligands, more specifically 
endothelial cells are a large source of Jagged 1 and Jagged 2 (38). Additionally, the loss of 
Jagged 1 (one of several Notch ligands) from endothelial cells using the VE-Cad-Cre;Jag1fl/fl
mouse results in a significant decrease in the number of immunophenotypic HSCs in the bone 
marrow along with impaired long-term reconstitution in limited dilution assays and competitive 
transplants (38). While this data suggested a direct Notch signaling between endothelial cells 
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and HSCs, later studies have demonstrated that the mechanism of Notch-mediated regulation 
of HSCs is non-cell autonomous. Expression of the Notch inhibitor, dominant negative 
Mastermind-like1 (DNMAML), in the HSC pool leads to no impairment in HSC function (40). 
However, this does not discount the importance of endothelial-derived Notch ligands and their 
role in HSC maintenance and just further shows that the mechanism for how Notch signaling 
regulates the HSC pool has yet to be fully elucidated. Pleiotrophin (PTN) is another known HSC 
regulatory molecule and using the PTN-GFP reporter mouse, researchers were again able to 
restrict expression to endothelial cells and LepR+ perivascular cells (33). Reciprocal transplants 
of wild-type BM into PTN-/- recipients had severely impaired donor HSC engraftment as early as 
four weeks post-transplant (33). Additionally, treatment of mice with anti-PTN (to block PTN 
signaling to HSC) induced HSC mobilization out of the BM (33). 
While a lot of focus has been put on the specific signaling molecules secreted from endothelial 
cells that directly act on the associated HSCs, emphasis has also been placed on the intracellular 
signaling that influences EC function and the role of ECs as an HSC niche. Endothelial cells are 
continuously exposed to inflammation-inducing signals that target receptors on their surface 
leading to production of a range of pro-inflammatory signals like IL-1, IL-6, and TNFα. The 
induction of these inflammatory programs in ECs requires the master regulator, NF-kB. 
Researchers employed the Tie2:IkB-SS mouse model, which expresses a dominant negative
form of IkB under the control of the Tie2 promoter which irreversibly binds NF-kB (41). Steady-
state analysis of these mice show a significant increase in BM cellularity, an increase in the 
number of immunophenotypic HSCs, and a larger pool of quiescent HSCs (41) suggesting that 
loss of NF-kB signaling in ECs maintains a pro-HSC maintenance environment. While these 
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conditional deletion mouse models have allowed researchers to prove the importance of BMECs 
as a component of the HSC niche in vivo. However, we have only begun to scratch the surface
when it comes to fully understanding the mechanisms of communication and regulation that exist 
between HSCs and their niche during both homeostatic and regenerative conditions. 
VASCULAR REGENERATION IN THE BONE MARROW 
Myeloablation is a condition where the bone marrow is severely suppressed and blood cell 
production dramatically drops. This is typically a side effect of the pre-conditioning regimes prior 
to bone marrow transplant (BMT) performed in the clinical setting. While myeloablation is 
necessary to deplete diseased bone marrow and provide space for donor HSCs to home and 
engraft, these therapies – including both the use of chemotherapy and irradiation – heavily 
disrupt the bone marrow microenvironment. One of the most damaged stromal populations 
following myeloablative therapy are the bone marrow endothelial cells, more specifically, 
VEGFR2+VEGFR3+ sinusoidal endothelium (42). In the first few days following myeloablation in 
mice, sinusoidal endothelial cells (SECs) begin to dilate and regress leading to a discontinuous 
vascular network with increased vascular permeability and impaired blood vessel integrity (8, 
42-48), however, starting around ten days after myeloablation and BMT, vascular recovery 
begins with the emergence of new blood vessels and by four weeks from transplant 
hematopoietic output returns to normal (42,49). 
The ability of the SECs to reform into a functional sinusoidal network is also necessary for 
successful engraftment and reconstitution of the hematopoietic system (42). More specifically, 
one critical pathway for vascular – and hematopoietic – regeneration is signaling through 
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VEGFR2. Mice undergoing BMT that receive neutralizing antibody against VEGFR2 have severe 
cytopenia in the bone marrow and peripheral blood leading to significantly reduced circulating 
white blood cells (WBCs) and platelets, have a predominance of disorganized and hemorrhagic 
sinusoids, and have severely impaired survival. While conditional deletion of VEGFR2 during 
steady-state has no impact on hematopoiesis, use of the ROSA-CreER;Vegfr2flox/- mouse model
during bone marrow regeneration results in life-threatening pancytopenia and severely 
regressed SECs for up to ten days post-transplant (42). Additionally, following myeloablative 
therapy, expression of Tie2 increases on regenerating blood vessels. Tie2 is one of two tyrosine 
kinase receptors expressed by blood vessels that bind the family of angiopoietin proteins. The 
angiopoietins are important growth factors in the formation of new blood vessels.  Using the 
soluble decoy receptor Tie2-Fc, researchers were able to test the importance of this signaling 
pathway in vascular recovery. Loss of free angiopoietins after myeloablation, leads to a 
significant delay in sinusoidal regeneration along with dramatic reductions in circulating WBCs 
and platelets (49). Additionally, radioprotection of bone marrow SECs using the Tie2-
Cre;Bak/Baxfl/fl mouse model, which deletes two pro-apoptotic genes specifically from BMECs,
results in increased protection of bone marrow HSCs, decreased vascular damage, and 
complete survival of the recipient mice post-transplant (48). These phenotypes were also 
observed in Angiopoietin 1 (Angpt1) global knockout models; while having no impact on the
vascular network during steady-state, loss of this signaling pathway during regeneration leads 
to slowed vascular recovery following lethal irradiation (46). Conversely, loss of NF-kB signaling 
in BMECs during bone marrow regeneration confers a protective effect. Mice lacking NF-kB have 
significantly less disruption of the sinusoidal network post myeloablation compared to wild-type 
controls (41).  As with SEC regeneration, loss of NF-kB in the BMECs following myeloablation 
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results in significantly faster recovery of mature circulating blood cells, with both red blood cells 
and platelets undergoing almost no change in peripheral blood concentration following irradiation 
and transplant compared to control mice (41). 
These pivotal studies have since generated the current paradigm surrounding vascular and 
hematopoietic regeneration following severe myeloablation and bone marrow damage. We now 
know that vascular recovery is a necessary precedent for hematopoietic reconstitution after 
BMT. However, this has opened the large question of what mechanisms drive vascular 
regeneration and whether these pathways can be manipulated in the clinical setting to improve 
the efficiency of BMT. While BMT is considered a curative treatment for many hematological 
diseases, the procedure itself puts patients at risk for severe – and potentially life-threatening – 
complications; all of which predominantly stem from the impaired or delayed ability of donor 
HSCs to successfully engraft in the bone marrow and reconstitute the hematopoietic system. 
Therefore, the ability to increase the rate of hematopoietic regeneration, through manipulation 
of the mechanisms driving vascular recovery, post-transplant has significant clinical importance. 
HEMATOPOIETIC AND STROMAL COMMUNICATION IS BI-DIRECTIONAL 
The interaction between the hematopoietic system and the bone marrow stroma is not one-
sided. While the importance of stromal-derived signaling for the proper function of the HSC pool 
is well described, studies over the past few years have implicated both mature blood cells and 
hematopoietic progenitors in communicating with the perivascular stromal populations in the 
bone marrow. More interestingly, this hematopoietic communication has been shown to 
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influence how the bone marrow stroma functions as niche. As mentioned above, CD169+ bone 
marrow macrophages are involved in the circadian oscillations of CXCL12 expression on LepR+ 
perivascular cells which directly influence the daily egress and homing of HSCs into and out of 
peripheral circulation (20-21). While the exact mechanism of communication remains elusive, 
chemical depletion of bone marrow macrophages using clodronate injections results in 
significantly decreased expression of Cxcl12 mRNA from LepR+ cells, as well as, a dramatic
increase in the number of circulating HSCs (20-21). Additionally, genetic depletion of bone 
marrow macrophages using the CD169DTR/+ mouse model, and subsequent dosing with diptheria
toxin, recapitulates these results as expression of Cxcl12 mRNA drops in the LepR+ cells and
the concentration of HSCs in circulation increases (21). Furthermore, use of macrophage-
conditioned media in Dexter bone marrow cultures (50) leads to increased production of CXCL12 
in the stromal cell line compared to the Dexter cultures grown in non-conditioned media 
suggesting a macrophage-derived soluble factor is involved (21). Additional research has linked 
this role of macrophage-induced regulation of the niche to clearance of aged neutrophils (22). 
Depletion of circulating neutrophils using an anti-LyG6 antibody is correlated with increases of 
Cxcl12 mRNA and protein levels in LepR+ perivascular cells. DsRed+ neutrophils injected into 
recipient mice also revealed that 40% of these neutrophils localize in direct contact with CD169+ 
macrophages. Additionally, DsRed+ macrophages can be found using flow cytometry, 
suggesting the engulfment of the aged DsRed+ neutrophils. Activation of LXR (liver X receptors), 
important transcriptional regulators that alter gene expression in macrophages following 
engulfment of apoptotic cells, using the agonist GW3965 leads to increased circulation of HSCs 
in the peripheral blood and a significant decrease in Cxcl12 expression in the bone marrow (22). 
While the specific factors transmitted from CD169+ macrophages to the LepR+ cells have yet to 
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be identified, this research implicated the importance of mature hematopoietic cells in regulating 
their own production via the HSC niches. Additionally, it is well known that Megakaryocytes 
produce a range of pro-angiogenic cytokines including VEGF-A (51), FGF-2 (52), and MMP-2 
(53) and the in vitro culturing of endothelial cells with platelets leads to increased cell proliferation
and vessel tube formation (54). In mice lacking the protein thrombospondin 1 (TSP 1), a protein 
restricted to Megakaryocytes and platelets, there is an increase in density of Megakaryocytes 
and increase in sinusoidal vasculature (55-56) suggesting that Megakaryocytes have both pro- 
and anti-angiogenic effects during homeostasis. 
The discovery that hematopoietic cells can influence the function of bone marrow stromal cells 
suggested that these mechanisms could have a role during regeneration. Additionally, it should 
be noted that following myeloablation to the bone marrow, lack of donor hematopoietic cells via 
a BMT not only results in lethality, but even more delayed vascular regeneration (42). While one 
explanation could be the need of BMECs for structural support provided by the presence of 
hematopoietic cells in the bone marrow, an alternative explanation is that hematopoietic cells 
communicate with the damaged BMECs to induce vascular recovery. As mentioned above, bone 
marrow Megakaryocytes are known to exist in a close relationship with the vasculature during 
homeostasis to allow for production of platelets. Under the stressed condition of hindlimb 
ischemia, it has also been shown that Megakaryocyte-derived cytokines found in platelets can 
accelerate new blood vessel formation (55). When researchers analyzed bone marrow 
regeneration following myeloablation in mice lacking the Megakaryocyte-derived anti-angiogenic 
factor TSP1, TSP-DKO, they noted faster recovery of platelets in the peripheral blood, reduced
damage to the sinusoidal vasculature following 5-FU treatment, and quicker recovery of the 
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vascular network to normal (56). Platelets derived from TSP-DKO mice also had increased
release of CXCL12 (56). Platelet-derived CXCL12 has been previously shown to induce 
recruitment of CXCR4+VEGFR1+ hematopoietic cells to the site of vascular injury to induce 
regeneration (57). 
Interestingly, the ability to impact vascular regeneration does not seem restricted to mature 
hematopoietic cells. Expression of Angpt1 in the bone marrow is restricted to Megakaryocytes,
hematopoietic progenitors, and LepR+ perivascular cells (46). Angpt1, and its receptor Tie2, are 
important for the development of the vascular system (58) and have been shown to have critical 
roles in vascular regeneration (48-49). To test the importance of LepR+ and hematopoietic 
progenitor cell derived Angpt1 on vascular regeneration, researchers lethally irradiated LepR-
Cre;Angpt1GFP/fl recipient mice and transplanted them with Mx1-Cre;Angpt1GFP/fl donor marrow.
Mice lacking Angpt1 in both populations experienced faster recovery of hematopoietic cells in 
peripheral blood, increased proliferation of BMECs in the bone marrow, and a faster recovery of 
regressed sinusoids (46). It should be noted, however, that loss of Angpt1 from hematopoietic 
cells alone had little to no improvement on recovery suggesting that LepR+ are the major 
functional source of Angpt1 in the context of vascular regeneration (46). Additionally, loss of 
Angpt1 in these transplant models did lead to higher levels of vascular permeability in the bone 
marrow, even 28 days post-transplant, suggesting that the vascular network in the BM is not 
functionally the same as before myeloablation (46). 
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 In chapter one of this thesis, I will present data that bone marrow neutrophils are directly 
involved in the regeneration of the bone marrow SECs through production of TNFα. Infused 
neutrophils localize directly in contact with the regenerating vasculature. Additionally, injection 
of recombinant TNFα results in a milder increase in vascular regeneration, compared to the
vascular recovery seen with adoptive transfer of neutrophils post-transplant. Taken together, this 
data suggests the potential of a regenerative neutrophil niche that is necessary for bone marrow 
regeneration. In chapter two of this thesis, I will present data that the composition of the gut 
microbiota communicates with the bone marrow to influence HSC proliferation and 
differentiation. Mice containing a microbiota that compositionally resembles that of a neonate 
contain HSCs with increased quiescence and myeloid-lineage bias in competitive transplant 
compared to mice harboring an adult gut microbiota. While we have yet to elucidate the 
mechanism driving this communication, we do know that the quiescent pool of HSCs is known 
to localize to the megakaryocyte (16) and arteriolar (8) niches. Therefore, this research could 
unveil a novel form of HSC niche modulation through signals emanating from the gut. 
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Figure 1. Schematic of the HSC niche. Hematopoietic stem cells (HSCs) reside in
specific regions of the bone marrow in close association with non-hematopoietic
stroma and mature hematopoietic cells. In addition, these regions are almost
exclusively perivascular and can be found along both sinusoidal and arteriolar blood
vessels. The endothelial network is a large component of the HSC niche and
endothelial cells comprising the blood vessels secrete a variety of critical factors that
maintain HSC function. LepR+ perivascular cells can be found in direct contact with
both sinusoidal and arteriolar vasculature and produce cytokines like CXCL12 and
SCF to directly regulate the associated HSCs. NG2+ perivascular cells are more
restricted to the arteriolar blood vessels and are more closely associated with
quiescent HSCs. Megakaryocytes are more restricted to the sinusoidal endothelium,
but also regulate HSC proliferation through production of factors like CXCL4 and
TGFβ. While these populations of the HSC niche directly regulate HSC function, there
are several other cell populations that indirectly contribute to HSC function through
interactions with the HSC niche. Sympathetic nerves follow along the arteries in the
bone marrow and influence HSC mobilization and trafficking by controlling CXCL12
production of the perivascular stromal cells through secretion of norepinephrine.
Additionally, bone marrow macrophages promote the retention of HSCs by also
regulating the production of CXCL12 of perivascular stromal cells. While the
mechanism is still unknown, this role of macrophages can be regulated by the daily
clearance of aged neutrophils via phagocytosis which leads to alterations in CXCL12
production of bone marrow perivascular stromal cells. Black arrows indicate direct
communication and regulation. Figure modified from one generated by Lucas lab
technician, Margot May.
FIGURE
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CHAPTER TWO: 
GRANULOCYTE-DERIVED TNFα PROMOTES VASCULAR AND HEMATOPOIETIC
REGENERATION IN THE BONE MARROW 
SUMMARY 
Endothelial cells are a critical component of the bone marrow (BM) stromal network that 
maintains and regulates hematopoietic cells (10-11,34-35,42,48,59-60). Vascular regeneration 
precedes, and is necessary for, successful hematopoietic stem cell (HSC) transplantation, the 
only cure for most hematopoietic diseases (42,48). Recent data suggest that mature 
hematopoietic cells may crosstalk with stromal cells to regulate their function (20-22,61). 
Whether a similar crosstalk regulates the vasculature is not known. Here we find that donor 
hematopoietic cells crosstalk with sinusoidal endothelial cells to induce host vessel and 
hematopoietic regeneration after transplantation. Adoptive transfer of BM, but not 
peripheral, granulocytes prevented death and accelerated recovery of host vessels and 
hematopoietic cells in mice transplanted with limited HSC numbers. Selective granulocyte 
ablation in vivo impaired vascular and hematopoietic regeneration after transplantation. Gene 
expression analyses indicated that granulocytes are the main source of the cytokine 
TNFα whereas its receptor, TNFR1, is selectively upregulated in regenerating vessels.  In
adoptive transfer experiments wild-type, but not Tnfa-/-, granulocytes induced vascular
recovery. After transplantation granulocytes are recruited to regenerating sinusoids suggesting 
that granulocytes crosstalk directly with endothelial cells. Accordingly, wild-type granulocyte
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transfer did not prevent death or promote vascular regeneration in Tnfr1-/-:Tnfr2-/- mice. Our
results indicate that BM granulocytes generate a microenvironment that promotes vessel 
growth and regeneration. Manipulation of the crosstalk between endothelial cells and 
granulocytes may lead to new therapeutic approaches to improve vessel regeneration and 
increase survival and hematopoietic recovery after HSC transplantation. 
INTRODUCTION 
Endothelial cells are a critical component of the bone marrow (BM) stromal network that 
maintains and regulates the production and function of hematopoietic cells (10-11,34-
35,42,48,59-60).  During steady-state hematopoiesis, the BM vasculature produce a wide 
range of angiocrine factors and chemokines, like CXCL12 (10-11), SCF (10-11), Pleiotrophin 
(32-33), and Notch ligands (34-35), that are required for the proper proliferation, differentiation, 
and retention or egress of maturing hematopoietic cells. Endothelial cells also have a large role 
during regenerative hematopoiesis following myeloablation and transplantation by producing 
factors that promote hematopoietic regeneration (33-35,48,62). Myeloablative therapies 
designed to remove diseased host hematopoietic cells severely damages BM blood vessels 
(8,42,48). Regeneration of the damaged vasculature must occur before endothelial cells can 
support hematopoiesis (41-42,48). Additionally, therapies that promote vessel survival and 
recovery also promote hematopoietic regeneration (41-42,48). While the current paradigm in 
the BM regenerative field places vascular regeneration as a necessary precedent for 
hematopoietic recovery, the mechanisms that drive endothelial cell regeneration are not well 
investigated. After myeloablation mice that received a bone marrow transplant showed faster 
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vascular regeneration than the control group that received no donor bone marrow (42). This 
suggested that hematopoietic cells are needed to promote vascular recovery. This, coupled 
with the fact certain hematopoietic cells are capable of communicating with and influencing the 
function of BM stromal cells prompted us to investigate the role of hematopoietic cells in 
driving bone marrow vascular regeneration. 
RESULTS 
To test whether hematopoietic cells crosstalk with the vasculature we transplanted different 
amounts of CD45.2+ bone marrow nucleated cells (BMNC) into lethally irradiated CD45.1+ 
recipients. Fourteen days later the transplanted mice showed a dose-dependent increase in 
the numbers of hematopoietic and CD45-Ter119-CD31+CD105+ endothelial cells in the BM 
(Fig. 2.1a,b and Supplementary Fig. 2.2a). To analyze the vascular network of these mice
we injected αCD31 and αCD144 antibodies intravenously followed by dissection and 3D 
whole-mount imaging of the sternal vasculature (8). This allowed us to distinguish between 
true vessels-with a perfused lumen- and vascular sheets that appear after vascular injury 
(Supplementary figures 1a,b). Mice transplanted with more BMNC showed a denser
vascular network with more numerous and longer vessels when compared to mice 
transplanted with fewer BMNC (Fig. 2.1c,d and Supplementary figures 1a,b). In agreement
with these results we found reduced vascular permeability (measured by Evans Blue 
extravasation, 22) in mice transplanted with higher amounts of donor BMNC (Fig. 2.1e). To 
test whether the endothelial cells were host or donor derived we transplanted WT mice with 
20x106 BMNC purified from Ubc-gfp mice which constitutively express GFP in all cells (63). We
found that virtually all endothelial cells were host derived (Fig. 2.1f). Transplant of more BMNC 
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led to increased endothelial cell recovery early after transplantation (Supplementary Fig. 
2.2b) and reductions in the fraction of apoptotic and necrotic endothelial cells (Supplementary
Fig. 2.2c) but had no effect on the cycling of endothelial cells (Supplementary Fig. 2.2d).
These experiments demonstrate that donor hematopoietic cells promote endothelial cell 
survival and drive the recovery of a functional, host-derived, vascular network in the recipient 
mice. 
The results above were surprising because hematopoietic progenitors were reported to inhibit 
vascular regeneration via angiopoietin-1 (46). We thus investigated whether the observed 
vascular recovery was mediated by more mature hematopoietic cells. We FACS-purified 
CD45.2+ hematopoietic cells based on the expression of mature lineage markers. We 
adoptively transferred each of these populations, at the same ratios found in vivo, into γ-
irradiated CD45.2+ recipients together with 105 CD45.1+ BMNC (as a source of donor HSC). 
Since the adoptively transferred cells are thought to have limited self-renewal capacity in vivo 
we adoptively transferred the same populations every 2-3 days for 2 weeks (Fig. 2.2a). We 
found that only Gr1+CD115- granulocytes, which contain all BM neutrophils and late neutrophil 
progenitors (21), were capable of inducing rapid recovery of endothelial cells (Fig. 2.2b). 
Notably, granulocyte transfer also promoted survival (Fig. 2.2c) and led to faster recovery of 
hematopoietic cells in the periphery (Fig. 2.2d). In agreement with previous studies (35,42,48) 
we found a strong correlation between endothelial cell recovery and survival as moribund mice 
showed less vascular recovery (Supplementary Fig. 2.3a). Imaging of the sternal vasculature
showed that granulocyte-treated mice had more blood vessels than PBS-treated controls or 
mice transferred with monocyte/macrophages, lymphocytes or erythroid-lineage cells (Fig. 
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2.2e,f). Granulocyte transfer also rescued vascular leakiness in irradiated mice but only when 
transferred at very high doses (Fig. 2.2g). Granulocyte-induced recovery was not mediated by 
induction of systemic inflammation as we did not detect significant increases in inflammatory 
cytokines in BM or plasma (Supplementary Fig. 2.3b), injury to peripheral tissues in
pathology analyses (Supplementary Fig. 2.3c), or increased granulocyte recruitment to
peripheral tissues (Supplementary Fig. 2.3d). We also did not find increased endothelial cell
recovery in peripheral tissues in granulocyte-treated mice (Supplementary Fig. 2.3e).
Transfer of common myeloid progenitors can protect lethally irradiated mice from death until 
the few host HSC that survived irradiation can restore hematopoiesis (64). To test if 
granulocytes induced survival through a similar mechanism we adoptively transferred 
granulocytes into lethally irradiated mice. We found that granulocytes were not capable of 
rescuing irradiation-induced death in the absence of donor hematopoietic stem and progenitor 
cells (HSPC, Supplementary Fig. 2.3f). We performed experiments following vascular and
hematopoietic recovery up to 4 weeks after transplantation (Fig. 2.2h and Supplementary 
Fig. 2.4a,b). These analyses revealed that granulocyte transfer promoted endothelial cell
survival early after transplantation as shown by reduced numbers of apoptotic and necrotic 
endothelial cells (Fig. 2.2i) and that was comparable to the one induced by transfer of high 
BMNC numbers (Supplementary Fig. 2.2c). In agreement, we found that granulocytes
induced expression of cFlip, an antiapoptotic prosurvival factor (65), in endothelial cells
(Supplementary Fig. 2.4c). In contrast granulocytes did not induce expression of
hematopoietic supportive molecules like Cxcl12, Scf, Notch ligands or led to activation of Hif1a
or its downstream targets (Supplementary Fig. 2.4d-f). These results indicate that
granulocytes promote endothelial cell survival. 
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To analyze the effect of granulocytes in hematopoietic recovery we performed lineage tracing 
experiments (Supplementary Fig. 2.5a). We found that the increased peripheral blood and
BM hematopoietic recovery was due to persistence of the transferred BM granulocytes 
(Supplementary Fig. 2.5d,g) and increased production of host cells in granulocyte-treated
mice (Supplementary Fig. 2.5c-h). Importantly, adoptive transfer of peripheral blood
neutrophils, which home to the bone marrow and crosstalk with CXCL12 abundant reticular 
stromal cells to regulate HSC trafficking (22), did not induce vascular or hematopoietic 
recovery (Supplementary Fig. 2.5b-h). This was probably because, in contrast to BM
granulocytes, peripheral neutrophils do not persist in the recipient mice (Supplementary Fig. 
2.5d,g). We hypothesized that increased vascular recovery might facilitate engraftment of
donor-derived HSPC. To test this, we performed competitive transplants. We FACS-purified 
donor CD45.1+ cells from the primary recipients and transplanted them together with 
competitor CD45.1+:CD45.2+ BMNC into lethally irradiated CD45.2+ secondary recipients, as 
this strategy allowed discriminating the origin of donor, competitor and recipient cells (Fig. 
2.2a). CD45.1+ BMNC from granulocyte-treated mice displayed increased short-term T- and 
myeloid cell, but not long-term (16 weeks) multilineage, contribution to peripheral blood (Fig. 
2.2j). Taken together our results demonstrate that adoptive transfer of BM granulocytes is 
sufficient to promote survival and drive vascular and hematopoietic cell recovery after 
myeloablation without exhausting the donor HSC pool. 
To investigate further the function of granulocytes in regeneration we bred Mrp8-cre-IRES-
GFP mice, in which Cre expression is largely restricted to granulocytes and a fraction of
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granulocyte monocyte progenitors (GMP, 66-67), with iDTR mice in which the diphtheria toxin
receptor (DTR) is induced by Cre-mediated recombination (68). To test whether granulocytes 
produced by the initial BMNC graft participated in vascular regeneration we transplanted 
lethally irradiated recipients with 5x106 BMNC purified from iDTR or Mrp8-cre-IRES-GFP:iDTR
mice followed by DT treatment. This led to efficient granulocyte ablation in the mice 
transplanted with Mrp8-cre-IRES-GFP:iDTR but not control iDTR BMNC (Fig. 2.3a,b). In these
mice, granulocyte ablation led to impaired vascular regeneration and increased vascular 
leakage (Fig. 2.3c-e) and impaired peripheral blood cell recovery (Fig. 2.3f). We also 
observed reductions in monocytes and macrophages in the BM of Mrp8-cre-IRES-GFP:iDTR
mice (Fig. 2.3g-i). To confirm that the monocyte/macrophage loss was not responsible for the 
reduced blood vessels we ablated granulocytes in vivo by injection of α-Ly6G, an antibody that 
ablates, exclusively, granulocytes (69). α-Ly6G, but not isotype control, treatment depleted 
granulocytes (Fig. 2.3j) and impaired vascular regeneration (Fig. 2.3k). It also caused loss of 
BM monocytes and lymphocytes (Supplementary Fig. 2.6a,b). Since α-Ly6G acts exclusively 
in granulocytes these results indicate that loss of these populations is due to granulocyte 
depletion. In a complementary approach we transplanted recipient mice with a single graft of 
total BMNC or a graft in which the granulocytes were removed prior to transplantation via 
FACS. As predicted, the mice transplanted with the granulocyte-depleted graft showed 
reduced granulocyte numbers (Fig. 2.3l) and impaired endothelial and hematopoietic 
regeneration 6 days after transplantation (Fig. 2.3m and Supplementary Fig. 2.6c,d). These
experiments demonstrate that donor-derived granulocytes are necessary for efficient vascular 
regeneration. 
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To investigate the mechanisms through which granulocytes promote vascular regeneration we 
profiled BM granulocytes for the expression of multiple angiogenic factors via qPCR. We 
detected expression of fibroblast growth factor 1 (Fgf1), progranulin (Prgn), pleiotrophin (Ptn), 
vascular endothelial growth factor a (Vegfa) and tumor necrosis factor alpha (Tnfa, 
Supplementary Fig. 2.7a). We focused on Tnfa because it was enriched in BM granulocytes 
(Supplementary Fig. 2.7b), its receptor Tnfr1 was enriched specifically in endothelial cells 
compared to the rest of the BM stroma (Supplementary Fig. 2.7c), Tnfr1 was upregulated in 
regenerating endothelial cells (Supplementary Fig. 2.7c) and TNFα induces cFLIP expression 
(70). TNFα is a powerful angiogenic factor in mice (71-72) and neutrophil-derived TNFα drives 
blood vessel formation during zebrafish development (73). Analyses of Tnfa-/- or Tnfr1-/-:Tnfr2-/-
mice revealed fewer endothelial cells in the steady-state bone marrow indicating that TNFα 
regulates vascular homeostasis (Supplementary Fig. 2.8). To test whether TNFα also played 
a role in regeneration we myeloablated WT or Tnfa-/- mice with a single injection of 5-
fluorouracil. We found that mutant mice displayed reduced endothelial cell numbers and 
dramatically succumbed to this treatment (Fig. 2.4a,b). Reduced Tnfa-/- mice survival might be
due to the reduced BM endothelial cell numbers in the steady-state. Because of this we also 
tested whether recombinant TNFα injection could be used to improve vascular regeneration.
Indeed, rTNFa injection induced faster vascular recovery in WT and Tnfa-/- mice and delayed
death in Tnfa-/- mice (Fig. 2.4a,b). These results indicate that TNFα regulates BM endothelial 
cell numbers during homeostasis and regeneration and that TNFα signaling can be modulated 
to improve vascular regeneration. To test whether granulocytes promoted vascular 
regeneration specifically via TNFα we performed adoptive transfer experiments using 
granulocytes purified from WT or  Tnfa-/- mice. To distinguish the effect in regeneration of
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sinusoids and arterioles we used Nestin-gfp mice as in this model Nestin-GFPbright cells label
arterioles (8,13). We found that WT, but not Tnfa-/- granulocytes, induced sinusoidal vessel
recovery as demonstrated by quantification of endothelial cells by FACS (Fig. 2.4c) and 
sinusoidal and arteriolar vessel numbers by 3D whole-mount immunofluorescence (Fig 
2.4d,e). In addition WT, but not Tnfa-/- granulocytes, rescued survival and drove faster white
and red blood cell recovery in the peripheral blood (Fig. 2.4f,g). Flow cytometry analyses 
showed that granulocytes express the membrane-bound form of TNFα (Supplementary Fig. 
2.9a). Imaging analyses showed that, during regeneration, granulocytes preferentially localized
to sinusoids with 76% of granulocytes found within 5µm of a sinusoid whereas a much smaller 
fraction (14%) localized to Nestin-GFPbright arterioles (Fig. 2.4h,i). B lymphocytes, which do not 
induce regeneration (Fig. 2.2b), showed fewer interactions with BM vessels (Supplementary 
Fig. 2.9b,c). Granulocyte recruitment to regenerating vessels was independent of CXCR4 and
CXCR2 (Supplementary Fig. 2.9d-f) which are the major receptors that regulate neutrophil
trafficking during homeostasis (74) indicating that additional mechanisms regulate granulocyte 
recruitment to injured vessels. The results above suggested that the crosstalk between 
granulocytes and endothelial cells was direct. In further support for this pathway, adoptive 
granulocyte transfer failed to promote survival and vascular regeneration in Tnfr1-/-:Tnfr2-/-
mice compared to control mice after transplantation (Fig. 2.4j,k). To confirm that granulocyte-
derived TNFα was not acting on hematopoietic cells we transplanted WT recipients with an 
initial graft of 105 WT or Tnfr1-/-:Tnfr2-/- BMNC followed by adoptive transfer of WT 
granulocytes. During regeneration TNFα acts on HSPC to promote engraftment (75). In 
agreement, we found reduced peripheral blood and BM hematopoietic recovery in 
mice transplanted with Tnfr1-/-:Tnfr2-/- BMNC (Supplementary Fig. 2.10a,b). We also found
delayed
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vascular regeneration (Supplementary Fig. 2.10c) likely due to insufficient granulocyte
production (Supplementary Fig. 2.10a). Adoptive transfer of WT granulocytes rescued death
(Supplementary Fig. 2.10d) and dramatically increased vascular and hematopoietic recovery
in both the mice transplanted with WT BMNC mice and in the mice transplanted with 
Tnfr1-/- :Tnfr2-/- BMNC  (Supplementary Fig. 2.10a,b). These experiments demonstrate that 
granulocytes crosstalk directly with the host BM stromal microenvironment via TNFα to drive 
vascular regeneration.  
DISCUSSION 
Myeloid cells are key players in vascular remodeling and regeneration in many tissues 
(71,73,76). Our results demonstrate that granulocytes, the most abundant cells in the BM, 
crosstalk with the microenvironment to drive vascular regeneration specifically via TNFα. Since 
both endothelial cell-derived factors (e.g. Notch ligands, EGF, Pleiotrophin (33-35,62,77) and 
vessel regeneration (41-42,48) are necessary for hematopoietic recovery our results suggest 
the existence of a bidirectional feedback loop after BM injury. In this loop endothelial cell 
regeneration will drive hematopoietic progenitor proliferation and generation of granulocytes 
which in turn support further vessel regeneration. Our results also indicate that granulocytes 
overcome the inhibition of vascular regeneration induced by hematopoietic progenitors (25). 
After transplantation HSC and multipotent progenitors preferentially generate myeloid cells 
(40), a preference believed to satisfy the physiological demand for peripheral neutrophils to 
prevent infections. Our results suggest that this myeloid bias might also contribute to recovery 
by forcing the differentiation of progenitors into granulocytes which in turn generate a 
microenvironment that promotes vessel regeneration and hematopoiesis. 
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The function of TNFα in regulation of HSPC is controversial. Some reports suggest that TNFα 
acts on HSPC to promote their maintenance in the steady state and engraftment during 
regeneration (75,78-80). Other reports suggest that TNFα acts on HSPC to inhibit their 
function during homeostasis and that TNFα-receptor blockade prior to transplantation promote
HSPC survival (81-82). Our results in Supplementary Figure 9 support a pro-regenerative 
effect of TNFα in HSPC. Our results also suggest that, in addition to its effects on 
hematopoietic cells, TNFα also regulates the vasculature and that granulocytes employ TNFα 
to crosstalk with the microenvironment to drive regeneration. Granulocytes also produce other 
pro-regenerative factors like VEGF, which is necessary for BM vascular regeneration (42) and 
that can recruit angiogenic myeloid cells to the heart (76), and Pleiotrophin which promotes 
hematopoietic recovery by inducing Ras activation in HSPC (33,62). Future studies will 
determine whether these factors cooperate with TNFα in granulocyte-driven regeneration.
Our data also suggest that the composition and cellular output of the initial graft affect recovery 
of host vessels and hematopoietic cells. This may have implications in the context of clinical 
HSC transplantation; in patients especially vulnerable to myeloablation, such as those with 
DNA repair defects or those in which the stroma has been damaged by prior chemotherapy 
treatment (83-85), a supply of BM granulocytes can be utilized to ameliorate vascular injury 
and promote hematopoietic recovery. 
MATERIALS AND METHODS 
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Mice 
C57BL/6J (CD45.2+) and B6.SJL-Ptprca Pepcb/BoyJ (B6.SJL, CD45.1+) were purchased from
the Jackson laboratory and bred in house. C57BL/6j:B6.SJL hybrids (CD45.2+:CD45.1+) were 
generated by breeding C57BL/6J with B6.SJL mice. Ubc-gfp mice (63), Mrp8-cre-IRES-gfp
(Mrp8-cre, 66), iDTR (68), Tnfa-/- (86) mice were originally purchased from the Jackson
laboratory. Tnfr1-/-:Tnfr2-/- (87) mice were also purchased from the Jackson laboratory and then
backcrossed for four additional generation into C57BL/6J background and then bred in house. 
Nestin-gfp mice (8,13) were a gift from Paul S. Frenette. All experiments were performed in 8-
14 week old male mice. All mice were housed at the SPF facility managed by the Unit for 
Laboratory Animal Medicine (ULAM) at the University of Michigan. Experiments were approved 
by the Institutional Animal Care and Use Committee at the University of Michigan. 
Bone marrow isolation. 
Mice were euthanized by isoflurane overdose. Bone marrow was harvested by flushing mouse 
long bones with 1 ml of ice-cold PEB (2mM EDTA 0.5% Bovine serum albumin in PBS). Red 
blood cells were lysed once by adding 1 mL of RBC Lysis Buffer (NH4Cl 150mM, NaCO3 
10mM, EDTA 0.1mM). Cells were immediately decanted by centrifugation, resuspended in ice-
cold PEB and used in subsequent assays. Due to the known effect of circadian rhythm effects 
in granulocytes and HSC (14,22,88-89) we performed BM harvest at zeitgeber times 3-6 in 
mice under standard (12h light:12h dark) cycles. 
Peripheral blood analyses. 
Blood was collected from the facial vein in tubes containing EDTA. White blood cell (WBC), red 
blood cell (RBC) and platelet counts were obtained using an Advia Counter (Siemens) or a 
Hemavet 950 (Drew Scientific). Prior to flow cytometry staining and analyses, red blood cells in 
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peripheral blood were lysed once by adding 1 mL of RBC Lysis Buffer (NH4Cl 150mM, NaCO3 
10mM, EDTA 0.1mM). Cells were immediately decanted by centrifugation, resuspended in ice-
cold PEB and used in subsequent assays. 
Collagenase/Dispase digestion 
To purify the stromal cell fraction of the bone marrow (including endothelial cells) we used a 
modified version of the serial digestion protocol developed by the Simmons laboratory (90). 
Digestion buffer was made using 2 mg/ml Collagenase Type IV (Gibco, 17104-019) and 3 
mg/ml Dispase (Gibco, 17105-041) dissolved in room temperature PBS. We harvested the BM 
by flushing a tibia with 1 ml of digestion buffer into a 5 ml polypropylene snap-cap tube 
containing another 1 ml of digestion buffer. We mixed the tubes vigorously by hand and 
incubated at 37°C for 5-7 minutes. Following the first incubation, the tubes were mixed 
vigorously by hand and then placed back at 37°C for another 5-7 minutes. After this second 
incubation we collected the supernatant taking care of leaving any macroscopic clumps in the 
tube. We transferred the digested cells to a tube containing 5 ml of ice-cold PEB. Then we 
added one ml of digestion buffer to the snap-cap tubes and the process above repeated until 
all macroscopic pieces of bone marrow had been digested. The red blood cells were lysed 
once using RBC Lysis Buffer, filtered through a 100 µm filter (Greiner Bio-one, 542-000), and 
then immediately spun down in the centrifuge. The cells were resuspended in 1 ml of ice-cold 
PEB and used for subsequent analyses. 
FACS analyses  
Cells were stained for 30 minutes in PEB buffer with the indicated antibodies and analyzed in a 
BD LSRFortessa (BD Biosciences) or FACS-purified using a BD FACS Aria II or a Synergy 
SY3200 Cell sorter (Sony). Dead cells and doublets were excluded based on FSC and SSC 
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distribution and DAPI (Sigma) exclusion. Data was analyzed using FACS Diva software 8.0 
(BDBiosciences). Antibodies used were against B220 (clone RA3-6B2, Cat No: 103224), CD3 
(clone 145-2C11, Cat No:100304), CD4 (clone GK1.5, Cat No:100422), CD8 (clone 53-6.7, 
Cat No:100722), CD11b (clone M1/70, Cat No:101216 or 101204), CD16/32 (clone 93, Cat 
No:101328), CD19 (clone 6D5, Cat No: 115508), CD31 (clone A20, Cat No:110724), CD41 
(clone MWReg30, Cat No:133921 or clone D7, Cat No: 108104), CD45 (clone 30-F11, Cat 
No:103116), CD45.1 (clone A20, Cat No:110723 or 110708), CD45.2 (clone 104, Cat 
No:109845, 109823 or 109814), CD105 (clone MJ7/18, Cat No:120410), CD115 (clone 
AFS98, Cat No:135506 or 135513), CD144 (clone BV13, Cat No: 138006), CD150 (clone 
TC15-12F12.2, Cat No:115904), F4/80 (clone BM8, Cat No:123122), Gr1 (clone RB6-8C5, Cat 
No: 108406 or 108404), Ly6-G (clone 1A8, Cat No: 127625), Sca-1 (clone D7, Cat 
No:108106), Secondary antibody (Goat anti-rat IgG, clone Poly4054, Cat No: 405418), and 
Ter119 (clone TER-119, Cat No:116220), all from Biolegend, CD117 (clone 2B8, Cat 
No:105828 and 105833 from Biolegend or 562417 from BD Biosciences), Ki67 (clone SolA15, 
Cat No:50-5698-82 from ThermoFisher Scientific), Ly6G (clone 1A8,  or Cat No: BP0075-1 
from Bioxcell) or isotype control (clone 2A3, Cat No: BP0089 from Bioxcell), TNFα (clone MP6-
XT22. Cat No: 506303). For cell cycle analyses cells were first fixed with 4% 
paraformaldehyde for 20 minutes at 4°C followed by permeabilization of the plasma membrane 
using 0.1% Triton X-100 for 20 minutes at 4°C. The cells were then stained for 30 minutes in 
PEB buffer containing 0.1% Triton X-100 with Ki67 (cat No:50-5698-82). Lastly, the cells were 
incubated in PEB buffer containing DAPI for one hour at room temperature before being 
analyzed as described above. Apoptotic cells were detected using the CellEvent™ Caspase-
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3/7 Green Flow Cytometry Assay Kit from Life Technologies (Cat No:C10427). Apoptotic cells 
were analyzed as described above.  
Primary and secondary bone marrow transplantation and adoptive transfer experiments 
Recipient male mice were conditioned with two doses of 600 rads, 3 hours apart, and 
immediately transplanted with the indicated amount of donor BMNC (retroorbital injection). For 
adoptive transfer experiments the indicated doses of FACS-purified hematopoietic cells were 
resuspended in 200µl of PBS and injected retroorbitally into the recipient mice. Due to the 
known effect of circadian rhythm effects in granulocytes and HSC (14,22,88-89) we performed 
adoptive transfers at zeitgeber times 10-12 in mice under standard (12h light:12h dark) cycles. 
In vivo granulocyte ablation.  
For diphtheria toxin-mediated granulocyte ablation we treated mice with daily intraperitoneal 
injections of diphtheria toxin (D0564, Sigma) (0.25µg/mouse/day) for one week starting one 
week after transplantation. For αLy6G-mediated depletion experiments we treated mice with
100µg (intraperitoneal) of αLy6G (clone 1A8, BP0075-1, Bioxcell) or isotype control (clone
2A3, BP0089, Bioxcell) at days 1, 3 and 5 after transplantation. Binding of αLy6G prevents 
staining with αGr1. This prevented us to use Gr1 to detect granulocytes in αLy6G-injected
mice. Thus, in these experiments, Ly6G+ granulocytes were detected by staining BM cells with 
isotype or αLy6G with 1µg/ml of αLy6G followed by staining with a secondary antibody 
(405418, Biolegend) 
5-fluorouracil treatment.  
For these experiments we injected mice (retroorbitally) with a single dose of 250mg of 5-
fluorouracil (Sigma) per kg of body weight in PBS. 
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Recombinant TNFα injection. 
For these we injected the mice (0.5µg/mouse, intraperitoneally) with recombinant mouse TNFα 
(718004, Biolegend) daily. 
AMD3100 and SBD  
AMD3100 (5mg/kg s.c) and SBD (0.3mg/kg, i.p. SB225002, Sigma) were injected 
intraperitoneally at days 1, 3, and 5 after transplantation and 1 hour before harvest. 
Quantification of inflammatory cytokines in plasma and bone marrow extracellular fluid. 
Inflammatory cytokines were detected by using the Legendplex Mouse inflammation panel 
(740446, Biolegend) and following manufacturer’s instructions. 
RNA isolation and qPCR analyses 
RNA isolation was performed using the Dynabeads mRNA direct kit (Life Technologies) 
following manufacturer’s instructions. cDNA synthesis was performed using the RNA to cDNA 
EcoDry Premix (Clontech) following manufacturer’s instructions. qPCR was performed using 
the SYBR Green Supermix Quanta Biosciences using a ABI PRISM 7900HT Sequence 
Detection System (Appliedbiosystems). Results were analyzed using SDS 2.4 software 
(Appliedbiosystems). Oligonucleotides used for amplification are enumerated in 
Supplementary Table 2.1. 
Whole-mount immunofluorescence analyses 
Imaging of the mouse BM sternal vasculature has been described previously (8). Briefly, mice 
were injected (retroorbitally) with 5µg of Alexa Fluor 647 anti-mouse CD31 (110724, 
Biolegend) and 5µg of Alexa Fluor 647 anti-mouse CD144 (138006, Biolegend). Twenty 
minutes later mice were euthanized by isoflurane overdose and the sterna retrieved. For each 
sternum we removed muscle and connective tissue using a scalpel. The sternum was then 
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divided into segments and each segment cut sagitally to expose the BM cavity. Segments 
were fixed in 4% paraformaldehyde (Sigma) in PBS for 20 minutes at room temperature, 
washed thrice in PBS and imaged immediately or incubated in blocking solution (20% Goat 
Serum (Sigma) in PBS) for two hours prior staining with antibodies. Granulocytes or B cells 
were detected by staining in a solution containing 2.5µg/ml Alexa Fluor 488 anti-mouse Ly6-G 
(Clone 1A8, Biolegend) or Phycoerythrin conjugated anti-mouse CD19 (Clone 6F5, Biolegend), 
5% Goat Serum (Sigma) in PBS for 3 days. Prior imaging each segment was glued to 35mm 
dishes and imaged in a Leica SP5 upright confocal microscope using a 20X, long-distance, 
water immersion objective, Hybrid detectors, and Leica Application Suite Advanced 
Fluorescence software. We acquired z-stacks (2.98µm between slices) 20-200µm depending 
on the position of the bone. Each slice measured 434.17 in the x axis and 434.17µm in the y 
axis and was 1024x1024 pixels. All images were acquired at room temperature. For Alexa 
Fluor 647 the wavelength of the excitation laser was 647 nm and emitted light detected 
between 660 to 720nm. For Alexa Fluor 488 the wavelength of the excitation laser was 488nm 
and emitted light detected between 500 to 540nm. For Phycoerythrin the wavelength of the 
excitation laser was 560nm and detection from 570 to 600nm. We used Fiji (91) software to 
generate 3D reconstructions and maximum projections from each image. Blood vessels 
numbers and length were counted manually in 3D reconstructions in order to be able to 
distinguish true vessels (with lumen) from vascular sheets (lacking lumen). Composite images 
of each sternum were assembled by stitching together the maximum projection images in 
Power Point (Microsoft).    
Vascular permeability 
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Mice received 200 µl of 0.5% Evans Blue Dye (Sigma Aldrich, E2129) in PBS via retro-orbital 
injection. Thirty minutes later mice were euthanized and perfused with 5 ml of PBS to remove 
excess Evans Blue from the vessels. To harvest the bone marrow, one femur was flushed with 
1 ml of ice-cold PEB. The cells were centrifuged and the supernatant containing the 
extravasated Evans Blue was removed and placed in a clean 1.5 ml tube. To analyze the 
amount of Evans Blue in the supernatant, samples were placed in a 96-well plate and read 
using a Spectramax 340PC from Molecular Devices with the absorbance measured set to 610 
nm. 
Pathology analyses 
Mice were euthanized by isoflurane overdose. Liver, lung, and intestine were removed, 
processed, embedded in paraffin, sectioned, and stained with hematoxylin/eosin by a necropsy 
technician in the In-vivo Animal Core (IVAC). We received the sections and did imaging 
analysis using an Olympus BX51 with a 20X dry objective lens. Images were captured using a 
DP-70 digital camera and the associated software. In-depth pathological analysis was 
performed by the veterinary pathologist of the IVAC. 
Statistics 
In most graphs of data, the actual values for each mouse are plotted and the means indicated. 
In others the means and standard errors are plotted. Sample size was not predetermined and 
all mice were included in the analyses.  Mice were randomly allocated to the different groups 
based on cage and litter size. For all experiments we aimed to have the same number of mice 
in the control and experimental groups. For all experiments, at the time of analyses, the 
investigator was blinded to the group allocation. The only exception was the blood vessel 
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quantification in 3D reconstructions of sternal segments. Statistical differences were calculated 
using two-sample T-tests (for experiments with two groups), ANOVA (3 or more groups) on log 
transformed data, or Log-Rank tests for survival analysis. 
Data availability 
The primary data that support the results described here are available upon reasonable 
request 
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Figure 2.1. Donor hematopoietic cells drive endogenous vascular regeneration after transplantation. (a,b) Number of
bone marrow nucleated cells (BMNC, a) and endothelial cells (EC, CD45-Ter119-CD31+CD105+, b) in the femur of B6-
SJL mice 14 days after lethal irradiation and transplant with the indicated amount of CD45.2+ BMNC. p-values were
calculated using 1-way ANOVA model comparing the 3 higher doses to the lowest dose. (c) Representative
composite image showing blood vessels (white, CD31/CD144) in the sternum of mice treated as in a. Scale bar
200mm. (d) Quantification of intact blood vessel segments (left, one dot=one mouse) or average vessel length (right,
one dot=one vessel) in the sternum of mice treated as in a. p-values were calculated using Two-sample T-test. (e)
Quantification of extravasation of the dye Evans Blue in the bone marrow extracellular fluid of mice treated as in a. p-
values were calculated using Two-sample T-test. (f) Percentage of GFP+ endothelial cells in B6-SJL CD45.1+
recipients transplanted with 20x106 BMNC purified from Ubc-gfp mice. Unless otherwise indicated each dot
corresponds to one mouse. For all panels the graphs show the pooled data of at least two independent experiments.
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Figure 2.2. Granulocytes promote vascular regeneration. (a) Experiment design, (b) Number of endothelial cells (EC,
CD45-Ter119-CD31+CD105+) in the femur of C57BL/6 mice 14 days after lethal irradiation and transplant of 105
CD45.1+ BMNC followed by adoptive transfer of all the granulocytes (G: Gr1+CD115-, 1x106), monocytes and
macrophages (MO: CD115+ or F4/80+ cells within the Gr1-CD4-CD8-B220- gate, 1x105), lymphocytes (L: CD4+, CD8+
and B220+ cells, 7.5x105) and erythroid (E: Ter119+, 1x105) cells found in 2x106 CD45.2+ BMNC. p-values were
calculated using 1-way ANOVA model. (c,d) Survival curves (c, PBS n=5, G n=6, MO n=7, L n=6, and E n=6) and
peripheral blood recovery for mice treated as in b; each dot represents one mouse. p-values were calculated using
Log Rank analyses or one-way ANOVA. (e) Representative composite image showing blood vessels (white,
CD31/CD144) in sternal segments purified from PBS, granulocyte, monocytes and macrophages, lymphocytes or
erythroid cells-treated mice fourteen days after lethal irradiation and transplantation. Scale bar 200µm. (f)
Quantification of intact blood vessel segments (left, one dot=one mouse) or average vessel length (right, one dot=one
vessel) in the sternum of the mice shown in e. p-values were calculated using one-way ANOVA. (g) Quantification of
extravasation of the dye Evans Blue in the bone marrow extracellular fluid of transplanted mice treated with PBS or
serial adoptive transfer of 106 or 107 granulocytes fourteen days after the initial transplant. p-values were calculated
using one-way ANOVA. (h) Kinetics of endothelial cell recovery in PBS or granulocyte (G) treated mice at the
indicated time points. Each dot represents one mouse. p-values were calculated using Two-sample T-test. (i)
Frequency of live, apoptotic or necrotic endothelial cells, determined by caspase 3 staining, in the BM of mice treated
with PBS or granulocytes 6 days after transplantation. Each dot represents one mouse. p-values were calculated
using Two-sample T-test. (j) CD45.1+ cell engraftment in total, B, T or myeloid cells in secondary recipients after
transplantation of 2.5x105 CD45.1+:CD45.2+ competitor BMNC and 20% of the CD45.1+ cells in one femur of
granulocyte- or PBS-treated mice 14 days after initial transplant. PBS, n=18 for weeks 2-8, n=13 for weeks 10-16;
Granulocytes n=17 for weeks 2-8, n=12 for weeks 10-16. p-values were calculated using Two-sample T-test. For all
panels the graphs show the pooled data of at least two independent experiments.
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Figure 2.3. Granulocytes are necessary for vascular regeneration. (a, b) Gr1+CD115- granulocyte
quantification (a) and representative FACS plots (b) showing granulocyte depletion in lethally irradiated
C57BL6/J mice fourteen days after transplant of 5x106 iDTR or Mrp8-cre:iDTR BMNC followed by
diphtheria toxin treatment. (c) Number of endothelial cells (EC, CD45-Ter119-CD31+CD105+) in the femur
(left panel) and number and length of vessels in the sternum (right panel) of the mice analyzed in a. (d)
Representative composite image showing blood vessels (white, CD31/CD144) in sternal segments of
C57BL/6J mice treated as in a. Scale bar 200µm. (e) Evans Blue in the bone marrow extracellular fluid of
the mice shown in a. (f) Number of white blood cells (one dot = one mouse) and frequency of T cells (black
bar), B cells (white bar), monocytes (red bar) and neutrophils (grey bar), platelets and red blood cells in the
peripheral blood of mice treated as in a. (g-i) Monocyte (g), macrophage (h), and lymphocyte (i) numbers
in the bone marrow of the mice shown in a. (j,k) Ly6G+ granulocytes (j) and endothelial cells (k) in the BM
of lethally irradiated C57BL6/J mice 6 days after transplantation of 106 BMNC and treatment with isotype
control (Iso) or αLy6G antibodies. (l,m) Granulocytes (l) and endothelial cells (m) in the BM of lethally
irradiated C57BL6/J mice 6 days after transplantation of 106 BMNC (Ctrl) or a graft containing all other
hematopoietic cells but in which granulocytes have been removed via FACS. For all panels p-values were
calculated using Two-sample T-test and the graphs show the pooled data of at least two independent
experiments.
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Figure 2.4. Granulocytes promote vascular regeneration via TNFα. (a) Survival curves for WT or Tnfa-/-
mice after injection of 250mg/kg body weight of 5-fluorouracil (5FU) and treatment with either PBS (WT
n=18, Tnfa-/- n=16) or recombinant TNFα (WT n=7, Tnfa-/- n=4). p-values were calculated using Log Rank
analyses. (b) Number of endothelial cells in the femur of C57BL/6 mice treated as in a, 8 days after 5FU
injection. p-values were calculated using Two-sample T-test. (c) Number of endothelial cells in the femur
of C57BL/6 mice 14 days after lethal irradiation and transplant of 105 CD45.1+ BMNC followed by
treatment with PBS or adoptive transfer of WT or Tnfa-/- mice granulocytes. p-values were calculated using
1-way ANOVA model. (d) Quantification of the number (one dot=one mouse) and length (one dot= one
vessel) of intact sinusoidal and arterial segments in the sternum of the mice shown in c. p-values were
calculated using 1-way ANOVA model. (e) Representative composite image showing blood vessels (white,
CD31/CD144) in sternal segments of mice treated with PBS, WT or Tnfa-/- granulocytes. Scale bar=200µm
(f) Survival curves for the mice treated as in c (PBS n=5, WT n=6, Tnfa-/- n=8). (g) Number of white blood
cells (one dot = one mouse) and frequency of T cells (black bar), B cells (white bar), monocytes (red bar)
and neutrophils (grey bar), platelets and red blood cells in the peripheral blood of mice treated as in c. p-
values were calculated using 1-way ANOVA model. (h) Percentage of granulocytes (n=305 granulocytes
from two mice) found at the indicated distances from sinusoids (black) or arterioles (white) in Nestin-gfp
mice 6 days after lethal irradiation and transplant of 106 BMNC. (i) Immunofluorescence analyses showing
the association between transferred granulocytes (magenta, Ly6G) and regenerating sinusoids (white,
CD31/CD144) and arterioles (white and green, CD31/CD144+Nestin-GFPbright) in the mice shown in h.
Scale bar=25µm. (j) Survival curves for WT or Tnfr1-/-:Tnfr2-/- mice after lethal irradiation and
transplantation of 105 CD45.1+ BMNC followed by treatment with PBS (WT n=13, Tnfr1-/-:Tnfr2-/- n=4) or
adoptive transfer of WT granulocytes (WT n=12, Tnfr1-/-:Tnfr2-/- n=6). p-values were calculated using Log
Rank analyses. (k) Endothelial cells per femur in mice treated as in j but 6 days after the initial transplant.
p-values were calculated using 1-way ANOVA model. In panels a-k the graphs show the pooled data of at
least two independent experiments.
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Legend for Supplementary Movies 2. (a,b) 3D reconstruction of endothelial cells 
(CD31/CD144+, white) in the sternum of a lethally irradiated mouse fourteen days after 
transplantation of 20x106 (a) or 0.1 x106 BMNC (b). True vessels (with lumen) are indicated by 
blue arrows and can be easily distinguished from vascular sheets that appear after irradiation 
(yellow arrows).
a
b
SUPPLEMENTAL FIGURES
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ab c d
Supplementary Figure 2.2. Kinetics of endothelial cell recovery. (a) Gating 
strategy for the quantification of CD45-Ter119-CD31+CD105+ endothelial cells. (b)
Number of live endothelial cells per femur in C57BL/6 mice 3 and 6 days after
lethal irradiation and transplant of the indicated amounts of BMNC (1: n=5 for day
3 and day 6; 200: n=5 for day 3 and day 6). (c) Frequency of live, apoptotic, or
necrotic endothelial cells, determined by caspase 3 staining, in the BM of mice
treated as in panel b, 6 days after transplantation (1: n=5; 200 n=5). (d) Frequency
of proliferating (Ki67+) endothelial cells in the BM of mice analyzed in panel c, 6
days after transplantation (1: n=5, 200: n=5). p values were calculated using a two-
tailed Two-sample T-Test. Each dot represents one mouse. Graphs show the
pooled data of at least two independent experiments. Bar graphs represent the
mean.
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Supplementary Figure 2.3. Donor granulocytes do not induce inflammation. (a) Endothelial 
cells per femur in moribund (n=4) or non-moribund (n=5) C57BL/6 mice 14 days after lethal
irradiation and transplant of 105 BMNC. (b) Levels of the indicated inflammatory cytokines in
plasma or bone marrow extracellular fluid in C57BL/6 mice 14 days after lethal irradiation and
transplant of 105 BMNC followed by treatment with PBS (white, n=4) or adoptive granulocyte
transfer (blue, n=5, as in Fig. 2a). (c) Representative histology microphotographs of
hematoxylin/eosin stained sections of the indicated organs in the mice analyzed in panel b
(PBS: n=4, Granulocytes: n=5). Scale bar 200μm. (d-e) Percentage of granulocytes (d) or 
endothelial cells (e) in the indicated organs of the mice analyzed in panel b (white: n=4, blue:
n=5). (f) Survival curves of C57BL/6 mice after lethal irradiation and treated with adoptive
transfer of granulocytes. n = 5. p values were calculated using two-tailed Two-sample T-Test.
Graphs show the pooled data of at least two independent experiments. Bar graphs represent
the mean.
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6uSSlementar\ )igure 2.4. Kinetics of bone marrow regeneration. (a) Number of total 
BMNC, Gr1+CD115- granulocytes, Gr1-CD115-F4/80+ macrophages, Gr1hiCD115+ 
monocytes, Gr1loCD115+ monocytes, Gr1-F4/80-B220+ B cells, Gr1-CD4+ and CD8+ T 
cells per femur in C57BL/6 mice at the indicated time points after lethal irradiation and 
transplant of 105 BMNC followed by treatment with PBS (D3: n=5, D6: n=5, D14: n=15, 
D28: n=8) or adoptive granulocyte transfer (D3: n=5, D6: n=5, D14: n=19, D28: n=13). 
(E) WBC, RBC and PLT in the peripheral blood of mice treated as in panel a. (cf) PCR ̀
analyses for cFlip (c), Scf and Ccl12 ̀ (d) , Dll1, Dll4, agged1, ̀ and agged2 ̀ (e), and 
if1a, ̀ Agpt2, Pigf, and Pdgfb (f) epression ̀ in endothelial cells sorted from C57BL/6 
mice 14 days after lethal irradiation and transplant of 105 BMNC followed by treatment 
with PBS (n=6) or adoptive granulocyte transfer (n=6). For all eperiments ̀ each dot 
represents one mouse. p values were calculated using two-tailed Two-sample T-Test. 
Graphs show the pooled data of at least two independent eperiments. ̀ Bar graphs 
represent the mean.
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Supplementary Figure 2.5. Lineage trace of hematopoeitic reconstitution. (a) 
Experimental design for lineage tracing donor derived hematopoietic cells. (b) Total
CD45-Ter119-CD31+CD105+ endothelial cells from C57BL/6 mice 2 weeks after lethal
irradiation and transplant of 105 CD45.1+ BMNC followed by treatment with PBS or
adoptive transfer of BM granulocytes (G) or peripheral blood neutrophils (N). (c) WBC
in the peripheral blood of mice treated as in panel a. (d) CD45.2+ Ubc-gfp- Gr1+CD11b+ 
neutrophils in the peripheral blood of mice treated as in a. (e) Host versus donor-derived
Gr1+CD11b+ neutrophils, B220+ B cells, CD4+ or CD8+ T cells, Gr1-CD11b+ monocytes,
RBC, and PLT in the peripheral blood of mice treated as in panel a. (f) Total BMNC per
femur in mice treated as in panel a. (g) Total CD45.2+ Ubc-gfp- Gr1+CD115-granulocytes per 
femur in mice treated as in panel a. (h) Host versus donor-derived Gr1+CD115- 
granulocytes, Gr1-CD115-F4/80+ macrophages, Gr1hiCD115+ monocytes, Gr1loCD115+ 
monocytes, Gr1-F4/80-B220+ B cells, Gr1-CD4+ or CD8+ T cells, and Lin-CD48-CD150+ HSC
per femur in mice treated as in panel a. For all experiments each dot represents one mouse
(PBS: n=9, G: n=8, N: n=10). Graphs show the pooled data of at least two independent
experiments. p values were calculated using one-way ANOVA model. Bar graphs
represent the mean.
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Supplementary Figure 2.6. Alternative methods of granulocyte depletion during 
regeneration. (a,b) Number of monocytes and macrophages (a) or B and T lymphocytes (b) in 
the bone marrow of lethally irradiated C57BL6/J mice 6 days after transplantation of 106 
BMNC and treatment with isotype control (Iso: n=6) or αLy6G (n=6) antibodies. (c,d) Number 
of monocytes and macrophages (c) or B and T lymphocytes (d) in the bone marrow of lethally 
irradiated C57BL6/J mice 6 days after transplantation of 106 BMNC (Ctrl: n=5) or a graft 
containing all other hematopoietic cells but in which granulocytes have been removed via 
FACS (Gran depleted: n=5). Each dot corresponds to one mouse. p values were calculated 
using a two-tailed two-sample T-Test. Bar graphs represent the mean.
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ab
Supplementary Figure 2.7. qPCR analysis for pro-angiogenic factors during regeneration. 
(a) qPCR analyses to detect expression of angiogenic factors in FACS-purified BM 
granulocytes (n=4). (b) Tnfa expression in FACS-purified bone marrow cells: B-cells (B, 
B220+, n=8), T-cells (T, CD4+ or CD8+, n=8), granulocytes (G, CD115-Gr1+, n=8), Gr1hi 
monocytes (Gr1hi MO, Gr-1hiCD115+, n=8), Gr-1lo monocytes (Gr1lo MO, Gr1lo B220-CD4-
CD8-CD115+, n=8), macrophages (MØ, Gr1-CD115-B220-CD4-CD8-F4/80+ n=8) or 
erythroid cells (Ery, Ter119+, n=8). Graphs show the pooled data of at least two 
independent experiments. (c) qPCR analyses for Tnfr1 and Tnfr2 expression in BM 
endothelial cells (EC; steady state: n=4, BMT: n=4) or CD45-Ter119-CD31- stromal cells (Str; 
steady state: n=4, BMT: n=3) in WT mice in the steady state (-) or 8 days (+) after bone 
marrow transplantation (BMT) with 106 BMNC. For all experiments each dot corresponds to 
one mouse. p-values were calculated using 1-way ANOVA model. Bar graphs represent the 
mean.
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Supplementary Figure 2.8. Endothelial cell numbers in Tnfa and Tnfr1:Tnfr2 null mice. (a) 
Number of endothelial cells in the bone marrow of wild-type (n=8), Tnfa-/- (n=6), or 
Tnfr1-/-:Tnfr2-/- (n=4) mice in the steady-state. Each dot corresponds to one mouse. p 
values were calculated using one way ANOVA. Bar graphs represent the mean.
49
ad e
f
c
b
Supplementary Figure 2.9. Donor granulocytes localize to regenerating vasculature. (a) 
Representative flow cytometry FACS plots showing expression of membrane-bound TNFα in 
Gr1+CD115- BM granulocytes purified from WT or Tnfa-/- mice. The experiment was repeated 
twice with a total of 4 mice per group. (b) Immunofluorescence analyses showing the 
association between transferred B cells (magenta, CD19), regenerating sinusoids (white, 
CD31/CD144) and arterioles (white and green, CD31/CD144+Nestin-GFPbright) in the sternum 
of Nestin-gfp mice 6 days after lethal irradiation and transplant of 106 BMNC. Scale 
bar=100µm. Images are representative of 3 mice in two different experiments. (c) Percentage 
of B cells (n= 69 B cells from three mice) found at the indicated distances from sinusoids 
(black) or arterioles (white) in Nestin-gfp mice 6 days after lethal irradiation and transplant of 
106 BMNC. Bar graphs represent the pooled data of three mice in two independent 
experiments. (d,e) Number of granulocytes (d) and endothelial cells (e) in the femur of 
C57BL/6 mice 6 days after transplant of 106 BMNC and treatment with PBS (n=4), AMD3100 
(CXCR4 antagonist, n=5) or SB225002 (CXCR2 antagonist, n=4). Each dot corresponds to 
one mouse. Bar graphs represent the mean for each group. (f) Percentage of granulocytes 
found at the indicated distances from CD31/CD144+ vessels in the sternum of PBS- (n=91 
granulocytes from three mice), AMD3100- (n=67 from three mice) or SB225002–treated 
(n=222 from three mice) mice. Bar graphs represent the pooled data of three mice in two 
independent experiments.
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aSupplementary Figure 2.10. TNFR1:TNFR2 in hematopoietic cells is dispensible during 
regeneration. (a) Total BMNC, Gr1+CD115- granulocytes, Gr1-CD115-F4/80+ macrophages, 
Gr1hiCD115+ monocytes, Gr1loCD115+ monocytes, Gr1-F4/80-B220+ B cells, Gr1-CD4+ or
CD8+ T cells per femur in C57BL\6 mice 2 weeks after lethal irradiation and transplant of
105 WT or Tnfr1-/-Tnfr2-/- BMNC followed by adoptive transfer of WT granulocytes. 
(b) WBC, RBC, and PLT in the peripheral blood of mice treated as in panel a.(c) Total
CD45-Ter119-CD31+CD105+ endothelial cells from mice treated as in panel a. WT + PBS
n=6, WT + Granulocytes n=6, Tnfr1-/-Tnfr2-/- + PBS n=5, and Tnfr1-/-Tnfr2-/- + 
Granulocytes n=6. (d) Survival curve of mice treated as in panel a. WT + PBS n=10, WT +
Granulocytes n=6, Tnfr1-/-Tnfr2-/- + PBS n=10, and Tnfr1-/-Tnfr2-/- + Granulocytes n=6. For all 
experiments one dot represents one mouse. p values were calculated using one-way
ANOVA model. Graphs show the pooled data of at least two independent experiments. Bar
graphs represent the mean.
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Supplementary Table 2.1. List of oligonucleotides used in qPCR experiments.
Gene Forward Reverse Reference
Angpt1 CATTCTTCGCTGCCATTCTG GCACATTGCCCATGTTGAATC 100
Angpt2 TTAGCACAAAGGATTCGGACAAT TTTTGTGGGTAGTACTGTCCATTCA 100
Ccl2 CCCACTCACCTGCTGCTACTCA GCTTCTTTGGGACACCTGCTG 101
cFlip GCTCCAGAATGGGCGAAGTAA ACGGATGTGCGGAGGTAAAAA 98
Cxcl12 CGCCAAGGTCGTCGCCG TTGGCTCTGGCGATGTGGC 14
Dll1 ACCTCGGGATGACGCCTTTG ACTCCCCTGGTTTGTCACAG 95
Dll4 CAGTTGCCCTTCAATTTCACCT AGCCTTGGATGATGATTTGGC 96
Ereg TGGGTCTTGACGCTGCTTTGTCTA AAGCAGTAGCCGTCCATGTCAGAA 102
Fgf1 GTTGACCCTACCATGTTCCCTTG GCCAGCAGCATCTATGGGAC 103
Fgf2 ACGGCGTCCGGGAGAA TCTTCTGGTTCGGCATCAC 104
Hif1a CTATGGAGGCCAGAAGAGGGTAT CCCACATCAGGTGGCTCATAA 99
Hgf GAACTGCAAGCATGATGTGG GATGCTGGAAATAGGGCAGAA 105
Jagged 1 GGTAACACCTTCAATCTCAAGGC CCACCAGCAAAGTGTAGGACC 106
Jagged 2 TGGTACCTGCGTGGATCAG AATAGCCGCCAATCAGGTT 106
Plgf ATGCAGATCTTGAAGATTCCC CTCTTCCCCTTGGTTTTCCT 92
Pdgb CATCCGCTCCTTTGATGATCTT GTGCTCGGGTCATGTTCAAGT 93
Pdgfa GAGGAAGCCGAGATACCCC TGCTGTGGATCTGACTTCGAG 93
Grn GGTTGATGGTTCGTGGGGATGTTG AAGGCAAAGACACTGCCCTGTTGG 94
Ptn TGGAGAATGGCAGTGGAGTGTGT TGGTACTTGCACTCAGCTCCAAACT 95
Scf CCCTGAAGACTCGGGCCTA CAATTACAAGCGAAATGAGAGCC 14
Tgfa ATCCTGTTAGCTGTGTGCCA GGAATCTGGGCACTTGTTGA 96
Tnfa CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG 97
Tnfr1 CCG GGAGAAGAGGGATAGCTT TCGGACAGTCACTCACCAAGT 107
Tnfr2 GCCCAGGTTGTCTTGACACC CACAGCACATCTGAGCCTTCC 108
Vegfa CAGAAGGAGAGCAGAAGTCC CTCCAGGGCTTCATCGTTA 92
Vegfb CCCAGTTTGATGGCCCCA TGCCCATGAGTTCCATGC 92
Vegfc GTAAAAACAAACTTTTCCCTAATTC TTTAAGGAAGCACTTCTGTGTGT 92
Vegfd GCAAGACGAGACTCCACTGC GGTGCTGAATGAGATCTCCC 92
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CHAPTER THREE: 
NEONATAL MICROBES RESTRICT PROLIFERATION AND INSTRUCT LINEAGE 
COMMITMENT OF HEMATOPOIETIC STEM CELLS 
INTRODUCTION AND RESULTS 
The work shown in the previous chapter demonstrated a critical role for BM granulocytes in 
regulating endothelial cells during regeneration. We then decided to investigate whether 
changing BM granulocyte numbers during homeostasis could also affect the vasculature. A 
study in the literature showed that gut microbes induced neutrophil production and 6-fold 
neutrophil accumulation in the bone marrow during neonatal development (109). In this study, 
depletion of the neonatal gut microbiota by antibiotic treatment leads to a significant impairment 
in production of neutrophils resulting in dramatically lower numbers of neutrophils in the BM and 
in circulation (109). This correlated with a decrease in G-CSF plasma levels and increased 
susceptibility to Escherichia coli K1 and Klebsiella pneumoniae sepsis (109). We hypothesized
that neonatal microbe-induced neutrophil expansion would also expand BM endothelial cells. To 
test this, and in collaboration with Dr. Gabriel Nuñez’s laboratory, we compared neutrophil and 
endothelial cell numbers in germ-free or SPF (P10) neonates housed in the UM vivarium. In 
contrast to the previous study (109) we did not find reduced neutrophil numbers in the germ-free 
neonates when compared to SPF controls (Fig. 3.1a). In agreement, endothelial cell numbers 
were also unaffected (Fig. 3.1b). We interpret the differences between our data and the one 
described in the literature as due to different gut microbe composition between different 
institutions, a well-known problem in the field (110-111). 
53
While performing these studies we thoroughly characterized the spectrum of mature and 
progenitor hematopoietic cells. We detected only very mild differences between pups born and 
raised in GF or SPF conditions (Supp. Fig 3.1a-d). However, we did discover a very striking 
HSC phenotype (Fig 3.1). Neonatal mice raised in SPF conditions had equal numbers of BM 
HSC to the GF cohort (Fig 3.1c) but had a significantly higher pool of Ki67- quiescent HSC 
compared to the GF group (Fig 3.1d,e). Shockingly, this difference in cell cycle status seems to 
be restricted to the HSC pool as the immediate downstream progenitor, the MPP, had the same 
total number (Fig 3.1c) and same percent of cycling MPPs (Fig 3.1d) in either group. To 
functionally test differences from HSC retrieved from neonates raised in SPF or GF conditions 
we initiated a competitive transplant where 20% of the BMNC from SPF or GF neonates was co- 
transplanted with 2.5x105 CD45.1 competitor into CD45.2 lethally irradiated recipients. Blood 
was taken every 2 weeks for 16 weeks to track tri-lineage reconstitution. Interestingly, HSC 
isolated from SPF neonates show a skewing towards myeloid and T lymphocyte lineages 
compared to the HSC isolated from GF neonates (Fig 3.1f). Additionally, recipients that received 
HSC from SPF neonates have high reconstitution in the peripheral blood (measured by total 
CD45.2+ cells) indicating higher HSC activity (Fig 3.1f). 
Our research was not the first to note a phenotype in the HSC pool when the gut microbiota is 
absent. In fact, in a previous report where researchers compared the BM of adult GF and SPF 
animals, they also noted no change to the size of the HSC pool in the BM (112). Additionally, 
the absence of a gut microbiota also induced large changes to the myeloid compartment 
including significant reductions in the number of BM and splenic macrophages and neutrophils, 
as well as, BM granulocyte-monocyte progenitors (GMPs). When these GMPs were placed in 
54
CFU assays, GMPs isolated from GF mice had reduced production of CFU-G and CFU-M 
colonies, as well as smaller colonies over all, compared to GMPs taken from SPF donors, 
suggesting that loss of a gut microbiota impairs the differentiation and proliferation of this 
progenitor population (112). While this research further supported the importance of the gut 
microbiota in maintaining proper production of mature myeloid cells, the function of the HSC in 
GF mice was never tested. In fact, no other parameters besides total number of HSC were ever 
investigated in this study. This leaves open the question of whether the GMP is the BM target of 
this communication emanating from the large intestine or if the reduction in GMPs is the result 
of impaired lineage differentiation from the HSC. 
Recently, a group reported the impact on the hematopoietic stem and progenitor cells in the BM 
after an antibiotic cocktail regiment including ampicillin, vancomycin, neomycin, metronidazole, 
and ciprofloxacin (113). Long-term exposure to antibiotics leads to bone marrow suppression 
which can cause anemia, thrombocytopenia, and neutropenia (113). If this is left unnoticed, this 
prolonged impairment to the hematopoietic system can lead to severe infection. While this 
phenotype is known to occur to patients in the clinic, there is still little known about the exact 
mechanisms that drive antibiotic-induced hematopoietic suppression. As expected, after two 
weeks of antibiotic drinking water, mice had suppression throughout the mature blood cell 
populations in the peripheral blood. More interestingly, however, was the suppression found 
within the BM as HSC were significantly reduced in mice that received antibiotics (113). 
Additionally, mice receiving antibiotic treatment also have a higher percentage of BrdU+ HSC 
than the control group. It should also be noted that mice receiving antibiotics have additional BM 
progenitor phenotypes with MPPs and CLPs also showing significant reductions in number, 
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however, only the HSC has any significant change in proliferation (113). Taken together with the 
previous research described, this data suggests that the BM phenotype emanates with changes 
to the HSC pool leading to a shift in the production of progenitors, however, as with the previous 
work the researchers in this group did not test HSC function. Additionally, germ-free mice were 
not treated with antibiotics to test for microbiota-independent effects to the BM 
microenvironment, the HSC niche, and hematopoietic cells themselves. 
The results in Fig. 3.1 demonstrated that HSC purified from SPF neonates have reduced 
proliferation, increased output after transplantation and are biased towards a myeloid fate. We 
then tested whether this was due to the gut microbiota. For this we initiated foster experiments 
to determine if the introduction of a gut microbiota to GF neonates following birth could induce 
the same BM phenotypes as mice born and reared in SPF conditions. SPF and GF females 
underwent timed breeding to generate litters born at the same time. Half of the pups born in GF 
conditions were immediately transferred to a SPF foster female. Ten days later, the BM of the 
SPF, GF, and GF pups fostered in SPF conditions were analyzed (Fig 3.2a). As shown in Fig. 
1, neonates raised in GF housing have increased proliferation within their HSC pool compared 
to SPF neonates with no change in the total number of HSC present in the BM (Fig 3.2b-c). 
Interestingly, GF neonates that were fostered in SPF conditions have an HSC profile much closer 
to SPF neonates than GF neonates (Fig 3.2c). HSC taken from fostered GF neonates have a 
quiescence signature mirroring that of HSC isolated from neonates born and raised in SPF 
housing (Fig 3.2c). While fecal samples were taken for analysis, we are currently waiting for the 
sequencing data to validate that the composition of the gut microbiota in GF neonates fostered 
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in SPF conditions mirrors the composition found in SPF neonates. Ultimately, this analysis could 
aid us in narrowing down the possible microbial candidates driving this communication. 
Next, we aimed to determine if this HSC phenotype was solely the result of developmental timing 
or if the introduction of a neonatal gut microbiota could influence HSC biology in an adult. The 
cecal contents of adult and neonatal (P5) mice were isolated and then adoptively transferred 
into adult GF recipients via oral gavage (Fig 3.2d). Three weeks after inoculation, bone marrow 
was harvested to test the HSC function and number. As predicted, the diversity of microbes in 
the large intestine varied greatly between the group receiving adult microbiota and the group 
receiving neonatal microbiota even three weeks after inoculation (Fig 3.2e). While the total 
number of HSC – along with other progenitor and mature blood populations – in the BM 
undergoes no change regardless of bacteria present, GF recipients that received the neonatal 
mixture contain a larger portion of quiescent HSC compared to GF recipients that received the 
inoculation of adult gut microbiota (Fig 3.2f-g, Supp. Fig 3.2a-c). To test for lineage skewing, 
we initiated a competitive transplant where CD45.1+ recipient mice received 20% of BMNC from 
mice inoculated with adult or neonatal gut microbiota along with 2.5x105 CD45.1+ competitor 
marrow (Fig 3.2h). Beginning six weeks post-transplant, recipients transplanted with BM from 
GF mice inoculated with neonatal microbiota produce a higher portion of myeloid cells in the 
peripheral blood against the competitor compared to the recipients that were transplanted with 
BM from GF mice that received adult microbiota (Fig 3.2h). As predicted we found increased 
peripheral blood reconstitution and bias towards myeloid and T cell lineages in recipient mice 
transplanted with BM cells purified from GF mice adoptive transferred with neonatal microbes 
(Fig. 3.2h). Taken together these experiments conclusively demonstrate that neonatal gut 
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microbes restrict proliferation and instruct lineage choices of HSC. Additionally, this data does 
suggest that it is the presence of a specific composition of bacteria in the large intestine that 
communicate with the BM to inhibit proliferation of the HSC pool and the prime the BM for 
specific hematopoietic cell production. Interestingly, when we analyzed the BM further we found 
that adult GF animals that receive a neonatal microbiota exhibit an expansion of their BM 
neutrophils (Supp. Fig 3.2c). However, this is not associated with an increase in BM endothelial 
cells (Supp. Fig 3.2d). 
While the GF model system allows us to test the role of the gut microbiota in a lower variable 
setting compared to treatment with antibiotic cocktails, the ease of using the system is low. The 
ability to accumulate enough mice for experimentation takes months and ultimately, we would 
need specific strains bred into the GF facility to test mechanism. In order to get around these 
issues, we began looking for additional models that mirror the neonatal gut microbiota 
phenotype. Previous research performed by the Nuñez lab demonstrated that adult SPF 
mice treated for three weeks with vancomycin induced a neonatal-like gut microbiota (114). 
Mice were treated with 250 µg/mL of vancomycin dissolved in their drinking water and three 
weeks after initiation of treatment, the mice were harvested for BM analysis. As with the 
adult GF mice treated with a neonate microbiota, adult SPF mice treated with vancomycin 
have increased HSC quiescence compared to the PBS control group (Fig 3.3b). However, 
SPF mice treated with vancomycin have mild expansion in several hematopoietic progenitor 
populations, including HSC (Fig 3.3a, Supp. Fig 3.3a-c), which was not an observed 
phenotype in either the neonatal studies or the adoptive transfer of gut microbiota studies. 
Interestingly, this data could suggest that vancomycin treatment impacts the gut microbiota 
composition in a way that induces only part of the 
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phenotype we see in the previous experiments. This could be due to incomplete removal of 
"adult" microbes that prevent expanded colonization of a more neonatal-like composition, as well 
as, impaired kinetics of the phenotype due to an ablation step followed by a recolonization step. 
Therefore, comparative fecal analysis of vancomycin-treated SPF adult animals, adult GF mice 
inoculated with neonatal gut microbiota, and true neonates will be necessary to determine any 
compositional differences in the intestinal bacteria of these groups. Additionally, HSC isolated 
from the vancomycin-treated and control groups need to be functionally tested in the competitive 
transplant setting to elucidate differences in engraftment and lineage skewing of mature cells in 
the peripheral blood. As mentioned previously, it is also important to compare bacterial diversity 
across the all different groups to 1) validate that our models are truly representative of a neonatal 
microbiota and 2) to aid in narrowing down potential bacterial candidates that could be important 
for this communication. 
DISCUSSION 
The colonization of the neonatal intestine following birth is connected to many alterations to the 
bone marrow and the secondary lymphoid organs associated with the intestine. These changes 
appear to be an important step in the maturation of the very naïve immune system for the 
neonate. Neutrophil production has been shown to dramatically increase following colonization 
of the gut and is an important step in protecting neonates from potentially life-threatening 
infections (109,115). Our results do not match this, and this could be due to the timing of our 
analysis, as well as, potential differences in gut microbiota of animals housed in different facilities 
(110-111). More specifically, the biggest differences in neutrophil numbers noted between GF 
and SPF neonates occur around P3, where SPF neonates have a ~10-fold increase in BM 
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neutrophils. By P7, that fold difference drops to ~2-fold (109). As all of our analyses fell on P10, 
it is possible that we missed the window for the initial expansion of BM neutrophils and the 
possible impact this could have on the developing BM vasculature. 
Additionally, research has also shown that hematopoietic stem and progenitor cells (HSPCs) are 
capable of sensing bacterial byproducts through expression of pathogen-associated molecular 
pattern (PAMP) receptors like the Toll-like receptors (TLR). In particular, activation of TLR4, 
through its ligand LPS, induces both HSC cycling and a skewing towards myeloid differentiation 
(116-121). In the context of acute infection this is a pathway to induce rapid production of 
neutrophils and monocytes to aid in the clearing of pathogens with the hematopoietic system 
returning to normal multi-lineage production following removal of the stressor. However, under 
the conditions of chronic infection and prolonged stimulation of TLRs, HSC function begins to 
deteriorate with severe impairment in long-term production of lymphocytes and decreased self- 
renewal of HSC in a competitive transplant setting suggesting an overall loss of HSC function in 
the presence of prolonged TLR activation (117-118). While this data has implicated an 
involvement of bacteria on HSC function it is all within the context of infection. As mentioned 
earlier, more recent studies have also begun elucidating the impact of the gut microbiota on 
steady-state hematopoiesis (109,112-113). While previous GF studies have been done during 
homeostasis (112), the HSC phenotypes do not entirely match ours. However, it is important to 
note that most of these previous studies do not hone in on the HSC population and fail to commit 
to functional studies to test the biology of HSC in mice with or without a gut microbiota (112- 
113). Even excluding the HSC phenotype, we do not observe many significant differences to the 
BM of adult mice raised in GF or SPF conditions (data not shown). It is important to note, our 
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research using the GF adults for adoptive transfer assays were done strictly using female GF 
recipients while males are typically used in other studies (112-113). This brings into the question 
the possibility of sex-based differences in how the hematopoietic system responds to the lack of 
a gut microbiota. Lastly, our research is novel in that we specifically investigated the importance 
of the composition of the gut microbiota – and not just the absence or presence – on steady- 
state hematopoiesis. More specifically, we identified the neonatal bacterial diversity of the gut 
as capable of inducing quiescence and myeloid cell production of the HSC pool. However, as of 
now we do not have much insight into the possible mechanistic pathways at work to drive this 
communication. 
Due to the increase in HSC quiescence, we can develop some hypotheses for how the gut 
microbiota might be targeting the BM. In particular, a change in the HSC pool immediately brings 
into question changes to the BM microenvironment and the HSC niche. Several non- 
hematopoietic and hematopoietic populations have been shown to provide signals that induce 
changes in the associated HSC. More specifically, the stromal Ng2+ perivascular population (8) 
and the megakaryocyte (16-19) have been connected to HSC quiescence. Preliminary data 
suggests an expansion of megakaryocytes in SPF neonates and in adult GF mice inoculated 
with neonatal microbiota (data not shown), however, as of now the pool size of these 
experiments is quite small and we have no mechanistic data to further support this observation. 
However, these two cell populations are potential mediators of this communication pathway. 
While this is interesting from the perspective of stem cell biology, our research might also have 
potential in the clinical setting. HSC quiescence has been shown to influence their engraftment 
success following bone marrow transplant with a larger quiescent pool of HSC being associated 
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with increased engraftment (122-123). Additionally, rapid production of myeloid cells following 
transplant is a necessary step to prevent life-threatening complications induced by rampant 
infection. Our data suggests that a gut microbiota that compositionally resembles that of a 
neonate induces a shift in hematopoietic lineage production towards the granulocytic and 
monocytic lineages. This large shift in neutrophil production was not just present in the bone 
marrow cavity but was also observed in the peripheral blood. This could be suggesting increased 
production of matured, functional granulocytes, but this needs to be further tested in an infection 
animal model with recipients inoculated with adult or neonatal gut microbiota. Taken together 
our data could suggest an important clinical role for the manipulation of the gut microbiota in 
aiding the success of bone marrow transplant to increase HSC engraftment and myeloid- 
skewing to bias production of neutrophils to prevent infection. 
MATERIALS AND METHODS 
Animals 
Specific pathogen free (SPF) C57BL/6J (CD45.2+) and B6.SJL-PtprcaPepcb/BoyJ (B6.SJL,
CD45.1+) mice were purchased from the Jackson laboratory and bred in house. SPF mice were 
housed at the SPF facility managed by the Unit for Laboratory Animal Medicine (ULAM) at the 
University of Michigan. C57BL/6J mice were also maintained on a germ-free (GF) background 
and were bred and maintained at the Germ-Free Animal Core Facility at the University of 
Michigan. GF mice were maintained in flexible film isolators and were checked weekly for GF 
status by aerobic and anaerobic culture. All experiments were performed on P10 neonates and 
8-14 week-old mice. Experiments were approved by the Institutional Animal Care and Use 
Committee at the University of Michigan. 
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Reconstitution of GF ice with cecal contents of defined bacteria 
Isolation, reconstitution, and inoculation of recipient mice were completed following the 
methods presented in the Nunez manuscript cited in the references, 114. 
Treatment with Vancomycin 
Vancomycin (250 mg/L) was administered in the mouse drinking water for 21 days. Water was 
replenished and fresh Vancomycin was added every 7 days. 
DNA extraction and 16S rRNA gene sequencing from fecal pellets 
DNA sequencing of fecal samples were completed following the methods presented in the 
Nunez manuscript cited in the references, 114. 
Bone marrow isolation 
Mice were euthanized with isoflurane overdose. Mouse long bones were flushed with 1 ml of 
ice-cold PEB (2mM EDTA, 0.5% Bovine serum albumin in PBS) to harvest bone marrow. Red 
blood cells were lysed once by adding 1 ml of RBC Lysis Buffer (NH4Cl 150mM, NaCO3 
10mM, EDTA 0.1mM). Cell suspension was immediately separated by centrifugation, 
supernatant was decanted, and harvest bone marrow cells were resuspended in ice-cold PEB 
and used in subsequent assays. 
Peripheral blood analyses 
Peripheral blood was collected from the facial vein in tubes containing EDTA. White blood cell 
(WBC), red blood cell (RBC), and platelet counts were obtained using an Advia Counter 
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(Siemens) or a Hemavet 950 (Drew Scientific). Prior to flow cytometry staining and analyses, 
red blood cells in peripheral blood were lysed once by adding 1 ml of RBC Lysis Buffer and 
incubating on ice for 5 minutes. Cells then underwent centrifugation to decant the supernatant. 
The cell pellet was resuspended in ice-cold PEB and used in subsequent assays. 
Collagenase/Dispase digestion 
To purify the stromal cell fraction of the bone marrow (including endothelial cells) we used a 
modified version of the serial digestion protocol developed by the Simmons laboratory (90). 
Digestion buffer was made by dissolving 2 mg/ml Collagenase Type IV (Gibco, 17104-019) and 
3 mg/ml Dispase (Gibco, 17105-041) in PBS at room temperature. Bone marrow was 
harvested by flushing a tibia with 1 ml of digestion buffer into a 5 ml polypropylene snap-cap 
tube containing another 1 ml of digestion buffer. Tubes were mixed vigorously by hand and 
incubated at 37°C for 5-7 minutes. Following the first incubation, the tubes were again mixed
vigorously by hand and then placed back at 37°C for another 5-7 minutes. After the second
incubation, the supernatant was collected (taking care to leave any macroscopic clumps in the 
digestion tube) and transferred the digested cells to a tube containing 5 ml of ice-cold PEB. 
Next, 1 ml of digestion buffer was added to the snap-cap tubes and the process above 
repeated until all macroscopic pieces of bone marrow had been digested. The red blood cells 
were lysed once using RBC Lysis Bugger, filtered through a 100 µm filter (Greiner Bio-one,
542-000), and immediately spun down in the centrifuge. The cell pellet was resuspended in 1 
ml of ice-cold PEB and used for subsequent analyses. 
FACS analyses 
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Cells were stained for 30 minutes in PEB buffer with the indicated antibodies and analyzed in a 
BD LSRFortessa (BD Biosciences). Antibodies used were against B220 (clone RA3-6B2, Cat 
No: 103224), CD3 (clone 145-2C11, Cat No:100304), CD4 (clone GK1.5, Cat No:100422), CD8 
(clone 53-6.7, Cat No:100722), CD11b (clone M1/70, Cat No:101216 or 101204), CD16/32 
(clone 93, Cat No:101328), CD31 (clone A20, Cat No:110724), CD41 (clone MWReg30, Cat 
No:133921 or clone D7, Cat No: 108104), CD45 (clone 30-F11, Cat No:103116), CD45.1 (clone 
A20, Cat No:110723 or 110708), CD45.2 (clone 104, Cat No:109845, 109823 or 109814), 
CD105 (clone MJ7/18, Cat No:120410), CD115 (clone AFS98, Cat No:135506 or 135513), 
CD144 (clone BV13, Cat No: 138006), CD150 (clone TC15-12F12.2, Cat No:115904), F4/80 
(clone BM8, Cat No:123122), Gr1 (clone RB6-8C5, Cat No: 108406 or 108404), Sca-1 (clone 
D7, Cat No:108106), and Ter119 (clone TER-119, Cat No:116220), all from Biolegend, CD117 
(clone 2B8, Cat No:105828 and 105833 from Biolegend or 562417 from BD Biosciences), and 
Ki67 (clone SolA15, Cat No:50-5698-82 from ThermoFisher Scientific). For cell cycle analyses, 
cells were first stained for immunophenotype. This was followed by fixation with 4% 
paraformaldehyde for 20 minutes at 4°C and then by permeabilization of the plasma membrane
with 0.1% Triton X-100 for 20 minutes at 4°C. The cells were then stained for 30 minutes in PEB
buffer containing 0.1% Triton X-100 with Ki67 (Cat No: 50-5698-82). Lastly, cells were incubated 
in PEB buffer containing DAPI for one hour at room temperature before being analyzed as 
described above.
Competitive bone marrow transplants 
Recipient SPF female mice were conditioned with two doses of 600 rads, 3 hours apart, and 
immediately transplanted with the indicated amount of donor BMNC via retroorbital injection. 
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Statistics 
In most graphs, the actual values for each mouse are plotted and the means indicated. In others, 
the means and standard errors are plotted. Sample size was not predetermined and all mice 
were included in the analyses. Mice were randomly allocated to the different groups based on 
cage and litter size. For all experiments, we aimed to have the same number of mice in the 
control and experimental groups. For all experiments, at the time of analyses, the investigator 
was blinded to the group allocation. Statistical differences were calculated using two-sample T-
tests (for experiments with two groups) and ANOVA (for experiments with 3 or more groups) on 
log transformed data. 
References 
Can be found at the end of dissertation. 
Publication 
This manuscript is currently ongoing in the Lucas lab as several experiments remain to be 
completed. 
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CHAPTER FOUR: 
CONCLUSION 
The BM is a complex structure containing many hematopoietic and non-hematopoietic cell 
populations that crosstalk to create a microenvironment that supports and regulates the 
production of mature blood cells. The best studied example of this complex crosstalk is the HSC 
niche. These niches are absolutely necessary for HSC maintenance through the production of 
a variety of signaling molecules. While many groups have and continue to investigate the 
mechanisms through which the niche regulates HSC much less is known about how the 
microenvironment functions downstream of HSC and how the different components of the 
microenvironment are regulated. The work done during my thesis has identified two novel forms 
of hematopoiesis regulation that impact the niche and hematopoietic cell production. 
Prior to my thesis, research had already discovered that BM endothelial cells are a large 
component of the HSC niche with production of critical HSC regulatory factors like SCF and 
CXCL12 (10-11). Additionally, studies performed in the context of regeneration and BMT placed 
vascular regeneration as a necessary precedent for the successful engraftment of the 
transplanted hematopoietic system (42,48). However, until now, very few mechanisms had been 
identified that induced vascular regeneration in the transplant setting. My thesis work uncovered 
a novel role for BM granulocytes in the regeneration and recovery of the vascular network and 
hematopoietic system in the BM. The adoptive transfer of BM-derived granulocytes increased 
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Figure 3.1 Gut microbes induce HSC quiescence in neonates. (a) Number of
Gr1+CD115- neutrophils in the femur of P10 neonates raised in germ-free
(GF) or specific pathogen free (SPF) housing (n=9-11). (b) Number of CD45-
TER119-CD31+CD105+ endothelial cells in the femur of the mice in a (n=9-
11). (c) Number of LSKCD150+CD105+ HSC (left, n=9-11) and of LSKCD150-
CD105- MPP (right, n=9-11) in the femur of mice in a. (d) Percent of quiescent
(Ki67-) LSKCD150+CD105+ HSC (left, n=9-11) and LSKCD150-CD105- MPP
(right, n=9-11) in the femur of the mice in a. (e) Representative FACS plots
showing the percent of Ki67- HSC from P10 GF (orange) or SPF (blue)
neonatal mice. (f) CD45.2+ cell engraftment of total, B, T, and myeloid cells in
secondary recipients after transplantation of 2.5x105 CD45.1+:CD45.2+
competitor BMNC and 20% of the CD45.2+ cell in one femur of GF or SPF
P10 neonates (n=7-10). For all experiments each dot represents one mouse.
p values were calculated using two-tailed Two-sample T-Test. Graphs show
the pooled data of at least two independent experiments. Bar graphs
represent the mean.
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Figure 3.2. Neonatal gut microbes restrict HSC proliferation. (a) Experimental 
design for fostering GF pups with a SPF dam. (b) Number of LSKCD150+CD105+ HSC in 
the femur of P10 neonates raised in GF, SPF, or GF fostered with a SPF dam housing 
(n=6-9). (c) Percent of quiescent (Ki67-) LSKCD150+CD105+ HSC in the femur of 
mice described in b (n=7-9). (d) Experimental design for adoptive transfer of gut 
microbes. (e) Microbial diversity in the large intestine of GF mice inoculated with adult 
(red) or neonatal (grey) gut microbiota. (f) Number of LSKCD150+CD105+ HSC (left, 
n=10-15) and LSKCD150-CD105- MPP (right, n=10-15) in the femur of GF mice (white) or 
GF mice inoculated with adult (red) or neonatal (blue) microbiota. (g) Percent of 
quiescent (Ki67-) LSKCD150+CD105+ HSC (left, n=10-14) and LSKCD150-CD105-MPP 
(right, n=10-14) in the femur of the mice in f. (h)
Representative FACS plots showing the percent of Ki67- HSC from GF mice inoculated 
with adult (left, red) or neonate (right, blue) microbiota.(i) CD45.2+ cell engraftment of 
total, B, T, and myeloid cells in secondary recipients after transplantation of 2.5x105 
CD45.1+:CD45.2+ competitor BMNC and 20% of the CD45.2+ cell in one femur of GF 
mice inoculated with adult (red) or neonatal (blue) microbiota (n=7-10). For all 
experiments each dot represents one mouse. p values were calculated using two-tailed 
Two-sample T-Test. Graphs show the pooled data of at least two independent 
experiments. Bar graphs represent the mean.
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Figure 3.3. Vancomycin-induced gut microbiota induces HSC
quiescence. (a) Number of LSKCD150+CD105+ HSC (left) and
LSKCD150-CD105- MPP (right) in the femur of mice treated with
Vancomycin (purple) or PBS (white), n=12. (b) Percent of
quiescent (Ki67-) LSKCD150+CD105+ HSC (left, n=12) and
LSKCD150-CD105- MPP (right, n=12) in the femur of the mice in
a. For all experiments each dot represents one mouse. p values
were calculated using two-tailed Two-sample T-Test. Graphs
show the pooled data of at least two independent experiments.
Bar graphs represent the mean.
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Supplemental Figure 3.1. (a) Number of total BMNC in the femur of P10
neonates raised in germ-free (GF, n=9), germ-free fostered in specific-
pathogen free (Foster, n=9), and specific pathogen free (SPF, n=11) housing.
(b) Number of LSKCD150-CD105- MPP, LKCD41-CD150-CD16/32+ GMP,
LKCD41-CD150-CD105-CD16/32- PreGM, LKCD150+CD41+ MkP, LKCD41-
CD16/32-CD150+CD105- PreMegE, LKCD41-CD16/32-CD150+CD105+
PreCFUe, LKCD41-CD16/32-CD150-CD105+TER119- ProEry, and LKCD41-
CD16/32-CD150-CD105+TER119+ CFUe in the femur of the mice described in
a, n=9-11. (c) Number of Gr1loCD115+ Monocytes, Gr1hiCD1115+ Monocytes,
Gr1-CD115-F4/80+ Macrophages, Gr1-CD115-F4/80-B220+ B cells, and Gr1-
CD115-CD4+ and Gr1-CD115-CD8+ T cells in the femur of mice described as
in a, n=9-11. (d) WBC, RBC and PLT in the peripheral blood of mice treated
as in a, n=6. For all experiments each dot represents one mouse. p values
were calculated using two-tailed Two-sample T-Test. Graphs show the pooled
data of at least two independent experiments. Bar graphs represent the mean.
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Supplemental Figure 3.2. (a) Number of total BMNC in the femur of GF
mice (white, n=15) or GF mice inoculated with adult (red, n=13) or neonatal
(blue, n=14) microbiota. (b) Number of LKCD41-CD150-CD16/32+ GMP,
LKCD41-CD150-CD105-CD16/32- PreGM, LKCD150+CD41+ MkP, LKCD41-
CD16/32-CD150+CD105- PreMegE, LKCD41-CD16/32-CD150+CD105+
PreCFUe, LKCD41-CD16/32-CD150-CD105+TER119- ProEry, and LKCD41-
CD16/32-CD150-CD105+TER119+ CFUe in the femur of the mice described in
a, n=13-15. (c) Number of Gr1+CD115- Neutrophils, Gr1loCD115+ Monocytes,
Gr1hiCD1115+ Monocytes, Gr1-CD115-F4/80+ Macrophages, Gr1-CD115-
F4/80-B220+ B cells, and Gr1-CD115-CD4+ and Gr1-CD115-CD8+ T cells in
the femur of mice described as in a, n=9-11. (d) Number of CD45-TER119-
CD31+CD105+ endothelial cells of mice treated as in a, n=13-15. For all
experiments each dot represents one mouse. p values were calculated using
two-tailed Two-sample T-Test. Graphs show the pooled data of at least two
independent experiments. Bar graphs represent the mean.
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Supplemental Figure 3.3. (a) Number of total BMNC in the femur of mice
treated with vancomycin (purple, n=18) or PBS (white, n=18). (b) Number of
LKCD41-CD150-CD16/32+ GMP, LKCD41-CD150-CD105-CD16/32- PreGM,
LKCD150+CD41+ MkP, LKCD41-CD16/32-CD150+CD105- PreMegE,
LKCD41-CD16/32-CD150+CD105+ PreCFUe, LKCD41-CD16/32-CD150-
CD105+TER119- ProEry, and LKCD41-CD16/32-CD150-CD105+TER119+
CFUe in the femur of the mice described in a, n=5-10. (c) Number of
Gr1+CD115- Neutrophils, Gr1loCD115+ Monocytes, Gr1hiCD1115+ Monocytes,
Gr1-CD115-F4/80+ Macrophages, Gr1-CD115-F4/80-B220+ B cells, and Gr1-
CD115-CD4+ and Gr1-CD115-CD8+ T cells in the femur of mice described as
in a, n=5-10. For all experiments each dot represents one mouse. p values
were calculated using two-tailed Two-sample T-Test. Graphs show the
pooled data of at least two independent experiments. Bar graphs represent
the mean.
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the overall number of endothelial cells present in the BM, as well as, the overall function of that 
vasculature (I.e. less permeability of the blood vessels) and significantly improved production of 
mature blood cells in circulation. Additionally, I also discovered that this crosstalk is in part 
mediated through the production of TNFα as the adoptive transfer of Tnfa-/- granulocytes into 
transplant recipients completely lost the ability to increase vascular and hematopoietic 
regeneration. While recombinant injection of TNFα does lead to some improvement in the 
regeneration of the BM, the regenerative effect is much milder in comparison to the adoptive 
transfer experiments. It is also interesting to note that imaging analysis of the adoptively 
transferred granulocytes suggests a specific localization of these cells compared to the same 
analysis done with adoptively transferred B lymphocytes, which appear to localize randomly in 
the regenerating BM, suggesting that membrane-bound TNFα may have a stronger regenerative 
effect than soluble forms. This observation could be important when discussing the clinical 
implications of this research. While this research was able to add to the growing mechanism that 
is BM regeneration, it has also opened up several other questions. While the adoptive transfer 
of granulocytes does increase vascular regeneration, we have very limited information regarding 
how the vasculature itself regenerates following BM damage. Initial mechanistic studies from 
this research suggest that granulocytes induce survival of the damaged endothelial cells as we 
noted increased expression of the pro-survival gene c-FLIP. However, the actual process that 
occurs to regenerate the damaged vasculature is unknown and is a current area of interest in 
our lab. Very preliminary studies using the Confetti mouse model under control of the vascular 
specific promoter VE-Cadherin suggests a possible patchwork mechanism where in damaged 
sinusoids re-associate with one another to reform the blood vessels (data not presented). This 
is contrary to the more well-defined mechanisms of sprouting and intussusceptive angiogenesis 
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and could provide insight into a novel form of blood vessel formation following severe vascular 
damage.  
 
The observation that granulocytes drive vascular regeneration fit within a larger narrative 
showing bidirectional communication between granulocytes and the vasculature. Granulocytes 
are the most abundant hematopoietic cell in the BM and are a critical component of the innate 
immune system and the inflammatory response. In order for granulocytes to egress from and 
home to the BM, they must migrate across an endothelial cell barrier. This process is dependent 
on the chemokine receptors CXCR2 and CXCR4, both expressed by granulocytes (74). CXCL1, 
CXCL2, and CXCL12 are all expressed by the BM vasculature and serve as ligands for these 
two receptors (74). Lack of CXCR2 expression leads to an accumulation of granulocytes in the 
BM space (124) while lack of CXCR4 in the BM leads to constitutive mobilization of granulocytes 
into the peripheral blood (125). The CXCR2/CXCR4 chemokine axis helps maintain the balance 
of granulocytes in the BM and in circulation. Similarly, granulocyte recruitment to tissues is 
regulated by the expression of adhesion molecules like selectins in the endothelial cell (126-
127). Granulocytes produce several known pro-angiogenic proteins like VEGF-A (128-129), 
CXCL8/IL-1 (130), CXCL1 (130), and HGF (131-132). Mice that have undergone antibody-
depletion of granulocytes lack the ability to induce angiogenesis into a Metrigel plug in vivo (133) 
from lack of release of VEGF-A (134-135), suggesting that recruitment of granulocytes to sites 
of wound healing or infection is required for the reformation of damaged blood vessels. 
Interestingly, this process is not restricted to the adult animal as research in zebrafish embryos 
has suggested a role for granulocyte-derived TNFα in the emergence of HSC from hemogenic 
endothelium (136). Loss of TNFα, its receptor TNFR2, or primitive granulocytes during 
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embryogenesis significantly impairs the budding of definitive HSC leading to a ~2-fold reduction 
in the HSC population (136). Thus, granulocytes and endothelial cells regulate each other in 
many biological processes including bone marrow regeneration.  
 
As mentioned, the data presented in chapter two of this thesis has clinical implication in the 
context of bone marrow transplantation. However, as presented, the process of granulocyte 
adoptive transfer would likely not be feasible, as the removal of bone marrow granulocytes from 
a healthy donor at multiple timepoints over the course of several weeks would be a technical 
challenge. While the research presented in chapter 2 discounts the use of peripheral blood 
neutrophils as an alternative source of TNFα (Supplementary Fig. 2.4b-h), this does not 
discount the possibility of 1) isolating G-CSF mobilized granulocytes from a healthy donor or 2) 
storing aliquots of bone marrow derived granulocytes from a healthy donor to be used for 
successive adoptive transfers. However, both of these potential alternative approaches have yet 
to be tested and are a continued focus of the research being conducted.  
 
We have also discovered that the composition of the gut microbiota is capable of influencing 
lineage differentiation decisions in the BM through alterations to the HSC pool. More specifically, 
we observed that the presence of a gut microbiota compositionally similar to a neonate leads to 
an increase in the fraction of HSCs that are quiescent and a skewing towards myeloid cell 
production that is maintained in competitive transplants. This was novel because we are the first 
lab to identify that signals emanating from the large intestine can influence HSC decisions in the 
BM during homeostasis as prior to this research most analysis concerning HSCs and the gut 
microbiota focused on infection and gut dysbiosis. However, there are many questions 
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surrounding the mechanism of communication that are still unknown. The most obvious open 
questions involve the bacterial species that are actively involved in this crosstalk. While we plan 
to do cross-comparative analysis of the fecal samples taken from all our experimental mice to 
hopefully narrow down potential bacterial candidates, it is likely to be more complex than a single 
species of bacteria. Additionally, the current signal(s) that are being sent to the BM to alter HSC 
function are unknown. Previous work investigating the increase in neutrophil production following 
the introduction of the gut microbiota after birth have identified G-CSF as a protein that increases 
in production after colonization (109) suggesting that known hematopoietic regulatory factors 
are likely involved in the phenotype we observe in the HSC pool. In addition, HSC quiescence 
has previously been linked to specific niche populations within the BM and an increase in the 
fraction of quiescent HSCs, with no change to the total number of HSC present, could suggest 
either 1) HSCs are re-localizing to niches that confer quiescence or 2) the niches are undergoing 
identity changes to switch from an "active" niche to a quiescent niche. While we do not observe 
any significant changes to the number of endothelial or LepR+ cells in the BM of mice with a 
neonatal gut microbiota, we have preliminary data that the neonatal composition leads to an 
increase in BM megakaryocytes – a known quiescent HSC niche (data not shown).  
 
In this thesis, we have identified two novel regulators of the hematopoietic microenvironment 
during regeneration (granulocytes) and homeostasis/development (gut microbes). These 
studies highlight the complex crosstalk that ensures that the hematopoietic system can adjust 
blood cell production to physiological demand.  
 
 
78
REFERENCES 
 
1. Asada N, Takeishi S, Frenette PS. Complexity of bone marrow hematopoietic stem cell 
niche. Int J Hematol. 106;45-54 (2017).  
2. Bribrair A, Frenette PS. Niche heterogeneity in the bone marrow. Ann NY Acad Sci. 
1370;82-96 (2016).  
3. Crane GM, Jeffery E, Morrison SJ. Adult haematopoietic stem cell niches. Nat Rev 
Immunol. 17;573-590 (2017).  
4. Ramalingam P, Poulos MG, Butler JM. Regulation of the hematopoietic stem cell 
lifecycle by the endothelial niche. Curr Opin Hematol. 24;289-299 (2017).  
5. Sanchez-Aguilera A, Mendez-Ferrer S. The hematopoietic stem-cell niche in health 
and leukemia. Cell Mol Life Sci. 74;579-590 (2017). 
6. Yu VW, Scadden DT. Heterogeneity of the bone marrow niche. Curr Opin Hematol. 
23;331-338 (2016).  
7. Chan CK, Chen CC, Luppen CA, Kim JB, DeBoer AT, Wei K, Helms JA, Kuo CJ, Kraft 
DL, Weissman IL. Endochondral ossification is required for haematopoietic stem-cell 
niche formation. Nature. 457;490-494 (2009).  
8. Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, Mizoguchi T, Wei 
Q, Lucas D, Ito K, Mar JC, Bergman A, Frenette PS. Arteriolar niches maintain 
haematopoietic stem cell quiescence. Nature. 502;637-643 (2013). 
9. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, 
Scadden DT, Ma’ayan A, Enikolopov GN, Frenette PS. Mesenchymal and haematopoietic 
stem cells form a unique bone marrow niche. Nature. 466;829-834 (2010).  
10. Ding L, Saunders TL, Enikopolov G, Morrison SJ. Endothelial and perivascular cells 
maintain haematopoietic stem cells. Nature. 481;457-462 (2012).  
11. Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors 
occupy distinct bone marrow niches. Nature. 495;231-235 (2013).  
12. Pinho S, Lacombe J, Hanoun M, Mizoguchi T, Bruns I, Kunisaki Y, Frenette PS. 
PDGFRα and CD51 mark human nestin+ sphere-forming mesenchymal stem cells 
capable of hematopoietic progenitor expansion. J Exp Med. 210;1351-1367 (2013).
79
 13. Asada N, Kunisaki Y, Pierce H, Wang Z, Fernandez NF, Birbrair A, Ma’ayan A, 
Frenette PS. Differential cytokine contributions of perivascular haematopoietic stem cell 
niches. Nat Cell Biol. 19;241-223 (2017).  
14. Mendez-Ferrer S, Lucas D, Battista M, Frenette PS. Heamatopoietic stem cell release 
is regulated by circadian oscillations. Nature. 452;442-447 (2008).  
15. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, Frenette PS. 
Signals from the sympathetic nervous system regulate hematopoietic stem cell egress 
from the bone marrow. Cell. 124;407-421 (2006).  
16. Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP, Kunisaki Y, Scheiermann C, Schiff 
L, Poncz M, Bergman A, Frenette PS. Megakaryocytes regulate hematopoietic stem cell 
quiescence thtough CXCL4 secretion. Nat Med. 20;1315-1320 (2014).  
17. Zhao M, Perry JM, Marshall H, Venkatraman A, Qian P, He XC, Ahamed J, Li L. 
Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration 
of the hematopoietic stem cells. Nat Med. 20;1321-1326 (2014).  
18. Nakamura-Ishizu A, Takubo K, Fujioka M, Suda T. Megakaryocytes are essential for 
HSC quiescence through production of thrombopoietin. Biochem Biophys Res Commun. 
454;353-357 (2014).  
19. Nakamura-Ishizu A, Takubo K, Kobayashi H, Suzuki-Onoue K, Suda T. CLEC-2 in 
megakaryocytes is critical for maintenance of the hematopoietic stem cells in the bone 
marrow. J Exp Med. 212;2133-2146 (2015). 
20. Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, Poulton IJ, van 
Rooijen N, Alexander KA, Raggatt LJ, Levesque JP. Bone marrow macrophages maintain 
hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood. 
116;4815-4828 (2010).  
21. Chow A, Lucas D. Hidalgo A, Mendez-Ferrer S, Hashimoto D, Scheiermann C, 
Battista M, Leboeuf M, Prophete C, van Rooijen N, Tanaka M, Merad M, Frenette PS. 
Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and 
progenitor cells in the mesenchymal stem cell niche. J Exp Med. 208;261-271 (2011). 
22. Casanova-Acebes M, Pitaval C, Weiss LA, Nombela-Arrieta C, Chevre R, A-Gonzalez 
N, Kunisaki Y, Zhang D, van Rooijen N, Silberstein LE, Weber C, Nagasawa T, Frenette 
PS, Castrillo A, Hidalgo A. Rhythmic modulation of the hematopoietic niche through 
neutrophil clearance. Cell. 153;1025-1035 (2013).  
23. Nilsson SK, Johnston HM, Coverdale JA. Spatial localization of transplanted 
hematopoietic stem cells: inferences for the localization of stem cell niches. Blood. 
97;2293–9 (2001). 
80
24.  Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family 
receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial 
niches for stem cells. Cell. 121;1109–21 (2005). 
25. Itkin T, Gur-Cohen S, Spencer JA, Schajnovitz A, Ramasamy SK, Kusumbe AP, 
Ledergor G, Jung Y, Milo I, Poulos MG, Kalinkovich A, Ludin A, Kollet O, Shakhar G, 
Butler JM, Rafii S, Adams RH, Scadden DT, Lin CP, Lapidot T. Distinct bone marrow 
blood vessels differentially regulate hematopoiesis. Nature. 532;323-328 (2016).  
26. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine 
receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 393;595–599 
(1998). 
27. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida 
N, Kikutani H, Kishimoto T. Defects in B-cell lymphopoiesis and bone-marrow 
myelopoiesis in mice lacking CXC chemokine PBSF/SDF-1. Nature. 382;635-638 (1996).  
28. Ara T, Tokoyoda K, Sugiyama T, Egawa T, Kawabata K, Nagasawa T. Long-term 
hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow 
ontogeny. Immunity. 19;254-267 (2003).  
29. Tzeng YS, Li H, Kang YL, Chen WC, Lai DM. Loss of Cxcl12/Sdf-1 in adult mice 
decreases the quiescent state of hematopoietic stem/progenitor cells and alters the 
pattern of hematopoietic regeneration after myelosuppression. Blood. 117;429-439 
(2011). 
30. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic 
stem cell pool by CXCL12–CXCR4 chemokine signaling in bone marrow stromal cell 
niches. Immunity. 25;977–988 (2006).  
31. Barker JE. Sl/Sld hematopoietic progenitors are deficient in situ. Exp Hematol. 
22;174-177 (1994). 
32. Himburg HA, Harris JR, Ito T, Daher P, Russell JL, Quarmyne M, Doan PL, Helms K, 
Nakamura M, Fixsen E, Herradon G, Reya T, Chao NJ, Harroch S, Chute JP. Pleiotrophin 
regulates the retention and self-renewal of hematopoietic stem cells in the bone marrow 
vascular niche. Cell Rep. 2;964-975 (2012). 
33. Himburg HA, Muramoto GG, Daher P, Meadows SK, Russell JL, Doan P, Chi JT, 
Salter AB, Lento WE, Reya T, Chao NJ, Chute JP. Pleiotrophin regulates the expansion 
and regeneration of the hematopoietic stem cells. Nat Med. 16; 475-482 (2010).   
34. Butler JM, Nolan DJ, Vertes EL, Varnum-Finney B, Kobayashi H, Hooper AT, Seandel 
M, Shido K, White IA, Kobayashi M, Witte L, May C, Shawber C, Kimura Y, Kitajewski J, 
Rosenwaks Z, Bernstein ID, Rafii S. Endothelial cells are essential for the self-renewal 
and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell. 6;251-
264 (2010).  
81
35. Poulos MG, Guo P, Kofler NM, Pinho S, Gutkin MC, Tikhonova A, Aifantis I, Frenette 
PS, Kitajewski J, Rafii S, Butler JM. Endothelial Jagged-1 is necessary for homeostatic 
and regenerative hematopoiesis. Cell Rep. 4;1022-1034 (2013).  
36. Rafii S, Shapiro F, Pettengell R, Ferris B, Nachman RL, Moore MA, Asch AS. Human 
bone marrow microvascular endothelial cells support long-term proliferation and 
differentiation of myeloid and megakaryocytic progenitors. Blood. 86;3353–3363 (1995).  
37. Lu LS, Wang SJ, Auerbach R. In vitro and in vivo differentiation into B cells, T cells, 
and myeloid cells of primitive yolk sac hematopoietic precursor cells expanded >100-fold 
by coculture with a clonal yolk sac endothelial cell line. P Natl Acad Sci USA. 93;14782–
14787 (1996).  
38.  Ohneda O, Fennie C, Zheng Z, Donahue C, La H, Villacorta R, Cairns B, Lasky LA. 
Hematopoietic stem cell maintenance and differentiation are supported by embryonic 
aorta-gonad-mesonephros region-derived endothelium. Blood. 92;908–919 (1998). 
39. Li W, Johnson SA, Shelley WC, Ferkowicz M, Morrison P, Li Y, Yoder MC. Primary 
endothelial cells isolated from the yolk sac and para-aortic splanchnopleura support the 
expansion of adult marrow stem cells in vitro. Blood. 102;4345–4353 (2003). 
40. Maillard I, Koch U, Dumortier A, Shestova O, Xu L, Sai H, Pross SE, Aster JC, 
Bhandoola A, Radtke F, Pear WS. Canonical notch signaling is dispensable for the 
maintenance of adult hematopoietic stem cells. Cell Stem Cell. 2;356-366 (2008).  
41. Poulos MG, Ramalingam P, Gutkin MC, Kleppe M, Ginsberg M, Crowley MJ, 
Elemento O, Levine RL, Rafii S, Kitajewski J, Greenblatt MB, Shim JH, Butler JM. 
Endothelial-specific inhibition of NF-κB enhances functional hematopoiesis. Nat 
Commun. 7;13829 (2016).  
42. Hooper AT, Butler JM, Nolan DJ, Kranz A, Iida K, Kobayashi M, Kopp HG, Shido K, 
Petit I, Yanger K, James D, Witte L, Zhu Z, Wu Y, Pytowski B, Rosenwaks Z, Mittal V, 
Sato TN, Rafii S. Engraftment and reconstitution of hematopoiesis is dependent on 
VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell. 4;263-74 
(2009).  
43. Knospe WH, Blom J, Crosby WH. Regeneration of locally irradiated bone marrow. I. 
Dose dependent, long-term changes in the rat, with particular emphasis upon vascular 
and stromal reaction. Blood. 28;398-415 (1966). 
44. Shirota T, Tavassoli M. Cyclophosphamide-induced alterations of bone marrow 
endothelium: implications in homing of marrow cells after transplantation. Exp Hematol. 
19;369-373 (1991). 
45. Kopp HG, Avecilla ST, Hooper AT, Shmelkov SV, Ramos CA, Zhang F, Rafii S. Tie2 
activation contributes to hemangiogenic regeneration after myelosuppression. Blood. 
106;505-13 (2005). 
82
46. Zhou BO, Ding L, Morrison SJ. Hematopoietic stem and progenitor cells regulate the 
regeneration of their niche by secreting Angiopoietin-1. Elife. 4;e05521 (2015).  
47. Li XM, Hu Z, Jorgenson ML, Wingard JR, Slayton WB. Bone marrow sinusoidal 
endothelial cells undergo nonapoptotic cell death and are replaced by proliferating 
sinusoidal cells in situ to maintain the vascular niche following lethal irradiation. Exp 
Hematol. 36;1143-1156 (2008). 
48. Doan PL, Russell JL, Himburg HA, Helms K, Harris JR, Lucas J, Holshausen KC, 
Meadows SK, Daher P, Jeffords LB, Chao NJ, Kirsch DG, Chute JP. Tie2(+) bone marrow 
endothelial cells regulate hematopoietic stem cell regeneration following radiation 
injury. Stem Cells. 31;327-37 (2013). 
49.  Kopp HG, Avecilla ST, Hooper AT, Shmelkov SV, Ramos CA, Zhang F, Rafii S. Tie2 
activation contributes to hemangiogenic regeneration after myelosuppression. Blood. 
106;505-513 (2005).  
50. T.M. Dexter, M.A. Moore, A.P. Sheridan. Maintenance of hemopoietic stem cells and 
production of differentiated progeny in allogeneic and semiallogeneic bone marrow 
chimeras in vitro. J. Exp. Med. 145;1612–1616 (1977). 
51.  Möhle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and 
thrombin-induced release of vascular endothelial growth factor by human 
megakaryocytes and platelets. Proc Natl Acad Sci USA. 94;663-668 (1997).  
52. Pintucci G, Froum S, Pinnell J, Mignatti P, Rafii S, Green D. Trophic effects of 
platelets on cultured endothelial cells are mediated by platelet-associated fibroblast 
growth factor-2 (FGF-2) and vascular endothelial growth factor 
(VEGF). Thromb Haemost. 88;834-842 (2002). 
53.  Fernandez-Patron C, Martinez-Cuesta MA, Salas E, Sawicki G, Wozniak M, 
Radomski MW, Davidge ST. Differential regulation of platelet aggregation by matrix 
metalloproteinases-9 and -2. Thromb Haemost. 82;1730-1735 (1999). 
54. Pipili-Synetos E, Papadimitriou E, Maragoudakis ME. Evidence that platelets 
promote tube formation by endothelial cells on matrigel. Br J Pharmacol. 125;1252-1257 
(1998). 
55. Amano H, Hackett NR, Rafii S, Crystal RG. Thrombopoietin gene transfer-mediated 
enhancement of angiogenic responses to acute ischemia. Circ Res. 97;337-345 (2005).  
56. Kopp HG, Hooper AT, Broekman MJ, Avecilla ST, Petit I, Luo M, Milde T, Ramos CA, 
Zhang F, Kopp T, Bornstein P, Jin DK, Marcus AJ, Rafii S. Thrombospondins deployed 
by thrombopoietic cells determine angiogenic switch and extent of revascularization. J 
Clin Invest. 116;3277-3291 (2006).  
57. Jin DK, Shido K, Hopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, 
Avecilla ST, Heissig B, Hattori K, Zhang F, Hicklin DJ, Wu Y, Zhu Z, Dunn A, Salari H, 
83
Werb Z, Hackett NR, Crystal RG, Lyden D, Rafii S. Cytokine-mediated deployment of 
SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat 
Med. 12;557-567 (2006).  
58. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato 
TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, 
during embryonic angiogenesis. Cell. 87;1171-1180 (1996). 
59. Kobayashi H, Butler JM, O’Donnell R, Kobayashi M, Ding BS, Bonner B, Chiu VK, 
Nolan DJ, Shido K, Benjamin L, Rafii S. Angiocrine factors from Akt-activated endothelial 
cells balance self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol. 
12;1046-1056 (2010). 
60. Greenbaum A, Hsu YM, Day RB, Schuettpelz LG, Christopher MJ, Borgerding JN, 
Nagasawa T, Link DC. CXCL12 in early mesenchymal progenitors is required for 
haematopoietic stem-cell maintenance. Nature. 495;227-230 (2013). 
61. Christopher MJ, Rao M, Liu F, Woloszynek JR, Link DC. Expression of the G-CSF 
receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization 
by G-CSF in mice. J. Exp. Med. 208;251-260 (2011). 
62. Himburg HA, Yan X, Doan PL, Quarmyne M, Micewicz E, McBride W, Chao NJ, 
Slamon DJ, Chute JP. Pleiotrophin mediates hematopoietic regeneration via activation of 
RAS. J Clin Invest. 124;4753-4758 (2014). 
63. Schaefer BC, Schaefer ML, Kappler JW, Marrack P, Kedl RM. Observation of 
antigen-dependent CD8+ T-cell/ dendritic cell interactions in vivo. Cell Immunol. 
214;110-122 (2001). 
 
64. Na Nakorn T, Traver D, Weissman, IL, Akashi K. Myeloerythroid-restricted 
progenitors are sufficient to confer radioprotection and provide the majority of day 8 
CFU-S. J Clin Invest. 109;1579-1585 (2002). 
 
65. Tsuchiya Y, Nakabayashi O, Nakano H. FLIP the Switch: Regulation of Apoptosis 
and Necroptosis by cFLIP. Int J Mol Sci. 16;30321-30341 (2015). 
 
66. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a 
myeloproliferative disorder arising from hematopoietic stem cells. Cell. 119;431-443 
(2004). 
 
67. Abram CL, Roberge GL, Hu Y, Lowell CA. Comparative analysis of the efficiency 
and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice. J 
Immunol Methods. 408;89-100 (2014).  
 
68. Buch T, Heppner FL, Tertilt C, Heinen TJ, Kremer M, Wunderlich FT, Jung S, 
Waisman A. A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation 
after toxin administration. Nat Methods. 2;419-426 (2005).  
84
 
69. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6G-specific 
monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol. 83;64-70 (2008).  
 
70. Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live 
or let die. Nat Rev Immunol. 15;362-374 (2015).  
 
71. Leibovich SJ, Polverini PJ, Shephard HM, Wiseman DM, Shively V, Nuseir N. 
Macrophage-induced angiogenesis is mediated by tumor necrosis factor-alpha. Nature. 
329;630-632 (1987).  
 
72. Baluk P, Yao LC, Feng J, Romano T, Jung SS, Schreiter JL, Yan L, Shealy DJ, 
McDonald DM.  TNF-alpha drives remodeling of blood vessels and lymphatics in 
sustained airway inflammation in mice. J Clin Invest. 119;2954-2964 (2009). 
 
73. Espin R, Roca FJ, Candel S, Sepulcre MP, Gonzalez-Rosa JM, Alcaraz-Perez F, 
Meseguer J, Cayuela ML, Mercader N, Mulero V. TNF receptors regulate vascular 
homeostasis in zebrafish through a caspase-8, caspase-2 and P53 apoptotic program 
that bypasses caspase-3. Dis Model Mech. 6;383-396 (2013).  
 
74. Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 
antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest. 
120; 2423-2431 (2010).  
 
75. Rezzoug F, Huang Y, Tanner MK, Wysoczynski M, Schanie CL, Chilton PM, 
Ratajczak MZ, Fugier-Vivier IJ, Ildstad ST. TNF-alpha is critical to facilitate hemopoietic 
stem cell engraftment and function. J Immunol. 180;49-57 (2008). 
 
76. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, 
Landsman L, Abramovitch R, Keshet E. VEGF-induced adult neovascularization: 
recruitment, retention, and role of accessory cells. Cell. 124;175-189 (2006). 
 
77. Doan PL, Himburg HA, Helms K, Russell JL, Fixsen E, Quarmyne M, Harris JR, 
Deoliviera D, Sullivan JM, Chao NJ, Kirsch DG, Chute JP. Epidermal growth factor 
regulates hematopoietic regeneration after radiation injury. Nat Med. 19;295-304 (2013).  
 
78. Pearl-Yafe M, Mizrahi K, Stein J, Yolcu ES, Kaplan O, Shirwan H, Yaniv I, Askenasy 
N. Tumor necrosis factor receptors support murine hematopoietic progenitor function in 
the early stages of engraftment. Stem Cells. 28;1270-1280 (2010).  
 
79. Rebel VI, Hartnett S, Hill GR, Lazo-Kallanian SB, Ferrara JL, Sieff CA. Essential 
role for the p55 tumor necrosis factor receptor in regulating hematopoiesis at a stem cell 
level. J. Exp. Med. 190;1493-1504 (1999). 
 
85
80. Slordal L, Warren DJ, Moore MA. Protective effects of tumor necrosis factor on 
murine hematopoiesis during cycle-specific cytotoxic chemotherapy. Cancer Res. 
50;4216-4220 (1990).  
 
81. Pronk CJ, Veiby OP, Bryder D, Jacobsen SE. Tumor necrosis factor restricts 
hematopoietic stem cell activity in mice: involvement of two distinct receptors. J. Exp. 
Med. 208;1563-1570 (2011).  
 
82. Ishida T, Suzuki S, Lai CY, Yamazaki S, Kakuta S, Iwakura Y, Nojima M, Takeuchi 
Y, Higashihara M, Nakauchi H, Otsu M. Pre-Transplantation Blockade of TNF-alpha-
Mediated Oxygen Species Accumulation Protects Hematopoietic Stem Cells. Stem 
cells. 35;989-1002 (2017).  
 
83. Lucas D, Scheiermann C, Chow A, Kunisaki Y, Bruns I, Barrick C, Tessarollo L, 
Frenette PS. Chemotherapy-induced bone marrow nerve injury impairs hematopoietic 
regeneration. Nat Med. 19;695-703 (2013). 
 
84. Galotto M, Berisso G, Delfino L, Podesto M, Ottaggio L, Dallorso S, Dufour C, 
Ferrara GB, Abbondandolo A, Dini G, Bacigalupo A, Cancedda R, Quarto R. Stromal 
damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant 
recipients. Exp Hematol. 27;1460-1466 (1999).  
 
85. Kemp K, Morse R, Wexler S, Cox C, Mallam E, Hows J, Donaldson C. 
Chemotherapy-induced mesenchymal stem cell damage in patients with hematological 
malignancy. Ann Hematol. 89;701-713 (2010).  
 
86. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory 
responses in follicular dendritic cell networks and germinal centers, and in the 
maturation of the humoral immune response. J Exp Med. 184;1397-1411 (1996).  
 
87. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier 
K, Morrissey PJ, Ware CB, Mohler KM. TNF receptor-deficient mice reveal divergent 
roles for p55 and p75 in several models of inflammation. J Immunol. 160;943-952 
(1998).  
 
88. Lucas D, Battista M, Shi PA, Isola L, Frenette PS. Mobilized hematopoietic stem cell 
yield depends on species-specific circadian timing. Cell stem cell. 3;364-366 (2008).  
 
89. Puram RV, Kowalczyk MS, de Boer CG, Schneider RK, Miller PG, McConkey M, 
Tothova Z, Tejero H, Heckl D, Jaras M, Chen MC, Li H, Tamayo A, Cowley GS, 
Rozenblatt-Rosen O, Al-Shahrour F, Regev A, Ebert BL. Core circadian clock genes 
regulate leukemia stem cells in AML. Cell. 165;303-316 (2016).  
 
90. Suire C, Brouard N, Hirschi K, Simmons PJ. Isolation of the stromal-vascular 
fraction of mouse bone marrow markedly enhances the yield of clonogenic stromal 
progenitors. Blood. 119;e86-95 (2012).  
86
 
91. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, 
Preibisch S, Rueden C, Saalfield S, Schmid B, Tinevez JY, White DJ, Hartenstein V, 
Eliceiri K, Tomancak P, Cardona A. Fiji: an open-source platform for biological-image 
analysis. Nat Methods. 9;676-682 (2012).  
 
92. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW. Angiogenesis gene expression 
profiling in xenograft models to study cellular interactions. Exp Cell Res. 299;286-293 
(2004). 
 
93. Tripurani SK, Cook RW, Eldin KW, Pangas SA. BMP-specific SMADs function as 
novel repressors of PDGFA and modulate its expression in ovarian granulosa cells and 
tumors. Oncogene. 32;3877-3885 (2013). 
 
94. Yu Y, Xu X, Liu L, Mao S, Feng T, Lu Y, Cheng Y, Wang H, Zhao W, Tang W. 
Progranulin deficiency leads to severe inflammation, lung injury and cell death in a 
mouse model of endotoxic shock. J Cell Mol Med. 20;506-517 (2016). 
 
95. Rosenfield SM, Bowden ET, Cohen-Missner S, Gibby KA, Ory V, Henke RT, Riegel 
AT, Wellstein A. Pleiotrophin (PTN) expression and function and in the mouse 
mammary gland and mammary epithelial cells. PLoS One. 7;e47876 (2012). 
 
96. Maekawa T, Sakuma A, Taniuchi S, Ogo Y, Iguchi T, Takeuchi S, Takahashi S. 
Transforming growth factor-alpha mRNA expression and its possible roles in mouse 
endometrial stromal cells. Zoolog Sci. 29;377-383 (2012). 
 
97. Tomita K, Freeman BL, Bronk SF, LeBrasseur NK, White TA, Hirsova P, Ibrahim 
SH. CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated 
Inflammation in Murine Nonalcoholic Steatohepatitis. Sci Rep. 6;28786 (2016). 
 
98. Wu YJ, Wu YH, Mo ST, Hsiao HW, He TW, Lai MZ. Cellular FLIP inhibits myeloid 
cell activation by suppressing selective innate signaling. J Immunol. 195;2612-2623 
(2015). 
 
99. Aro E, Khatri R, Gerard-O’Riley R, Mangiavini L, Myllyharju J, Schipani E. Hypoxia-
inducible Factor-1 (HIF-1) but not HIF-2 is essential for hypoxic induction of collagen 
prolyl 4-hydroxylases in primary newborn mouse epiphyseal growth plate chondrocytes. 
J Biol Chem. 287;37134-37144 (2012). 
100. Shih SC, Robinson GS, Perruzzi CA, Calvo A, Desai K, Green JE, Ali IU, Smith 
LE, Senger DR. Molecular profiling of angiogenesis markers. Am J Pathol. 161;35-41 
(2002). 
101. Aung HT, Schroder K, Himes SR, Brion K, van Zuylen W, Trieu A, Suzuki H, 
Hayashizaki Y, Hume DA, Sweet MJ, Ravasi T. LPS regulates proinflammatory gene 
87
expression in macrophages by altering histone deacetylase expression. FASEB J. 
20;1315-1327 (2006). 
102. Patel RD, Kim DJ, Peters JM, Perdew GH. The aryl hydrocarbon receptor directly 
regulates expression of the potent mitogen epiregulin. Toxicol Sci. 89;75-82 (2006). 
103. Du W, Prochazka J, Prochazkova M, Klein OD. Expression of FGFs during early 
mouse tongue development. Gene Expr Patterns. 20;81-87 (2016). 
104. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, Zadigue P, Dartevelle P, 
Simonneau G, Adnot S, Maitre B, Raffestin B, Eddahibi S. Endothelial-derived FGF2 
contributes to the progression of pulmonary hypertension in humans and rodents. J Clin 
Invest. 119;512-523 (2009). 
105. Hoot KE, Oka M, Han G, Bottinger E, Zhang Q, Wang XJ. HGF upregulation 
contributes to angiogenesis in mice with keratinocyte-specific Smad2 deletion. J Clin 
Invest. 120;3606-3616 (2010). 
106. Mourikis P, Gopalakrishnan S, Sambasivan R, Tajbakhsh S. Cell-autonomous 
Notch activity maintains the temporal specification potential of skeletal muscle stem 
cells. Development. 139;4536-48 (2012). 
107. White LE, Santora RJ, Cui Y, Moore FA, Hassoun HT. TNFR1-dependent 
pulmonary apoptosis during ischemic acute kidney injury. Am J Physiol Lung Cell Mol 
Physiol. 303; L449-459 (2012). 
108. Shanmugam G, Narasimhan M, Sakthivel R, Kumar RR, Davidson C, Palaniappan 
S, Claycomb WW, Hoidal JR, Darley-Usmar VM, Rajasekaran NS. A biphasic effect of 
TNF-alpha in regulation of the Keap1/Nrf2 pathway in cardiomyocytes. Redox Biol. 
9;77-89 (2016). 
109. Deshmukh HS, Liu Y, Menkiti OR, Mei J, Dai N, O’Leary CE, Oliver PM, Kolls JK, 
Weiser JN, Worthen GS. The microbiota regulates neutrophil homeostasis and host 
resistance to Escherichia coli K1 sepsis in neonatal mice. Nat Med. 20;524-530 (2017).  
110. Friswell MK, Gika H, Stratford IJ, Theodoridis G, Telfer B, Wilson ID, McBain AJ. 
Site and strain-specific variation in gut microbiota profiles and metabolism in 
experimental mice. PLoS One. 5;e8584 (2010). 
111. Moore RJ, Stanley D. Experimental design considerations in 
microbiota/inflammation studies. Clin Transl Immunology. 5;e92 (2016).  
112. Khosravi A, Yanez A, Price JG, Chow A, Merad M, Goodridge HS, Mazmanian SK. 
Gut microbiota promote hematopoiesis to control bacterial infection. Cell Host Microbe. 
15;374-381 (2014). 
88
113. Josefsdottir KS, Baldridge MT, Kadmon CS, King KY. Antibiotics impair murine 
hematopoiesis by depleting the intestinal microbiota. Blood. 129;729-739 (2017).  
114. Kim YG, Sakamoto K, Seo SU, Pickard JM, Gillilland MG 3rd, Pudlo NA, Hoostal M, 
Li X, Wang TD, Feehley T, Stefka AT, Schmidt TM, Martens EC, Fukuda S, Inohara N, 
Nagler CR, Nunez G. Neonatal acquisition of Clostridia species protects against 
colonization by bacterial pathogens. Science. 356;315-319 (2017).  
115. Sarkar S, Bhagat I, Hieber S, Donn SM. Can neutrophil responses in very low birth 
weight infants predict the organisms responsible for late-onset bacterial or fungal 
sepsis? J Perinatol. 26;501-505 (2006).  
116. Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S, Takatsu K, Kincade PW. 
Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system 
replenishment. Immunity. 24;801-812 (2006).  
117. Zhao Y, Ling F, Wang HC, Sun XH. Chronic TLR signaling impairs the long-
term repopulating potential of hematopoietic stem cells of wild type but not Id1 
deficient mice. PLoS One. 8;e55552 (2013). 
118. Esplin BL, Shimazu T, Welner RS, Garrett KP, Nie L, Zhang Q, Humphrey MB, 
Yang Q, Borghesi LA, Kincade PW. Chronic exposure to a TLR ligand injures 
hematopoietic stem cells. J Immunol. 186;5367-5375 (2011).  
119. Liu A, Wang Y, Ding Y, Baez I, Payne KJ, Borghesi L. Cutting Edge: 
Hematopoietic stem cell expansion and common lymphoid progenitor depletion 
require hematopoietic-derived, cell-autonomous TLR4 in a model of chronic 
endotoxin. J Immunol. 195;2524-2528 (2015). 
120. Herman AC, Monlish DA, Romine MP, Bhatt ST, Zippel S, Schuettpelz LG. 
Systemic TLR2 agonist exposure regulates hematopoietic stem cells via cell-
autonomous and cell-non-autonomous mechanisms. Blood Cancer J. 6;e437 (2016).  
121. Takizawa H, Regoes RR, Boddupalli CS, Bonhoeffer S, Manz MG. Dynamic 
variation in cycling of hematopoietic stem cells in steady state and inflammation. J 
Exp Med. 208;273-284 (2011).  
122. Lacorazza HD, Yamada T, Liu Y, Miyata Y, Sivina M, Nunes J, Nimer SD. The 
transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic 
cells. Cancer Cell. 9;175-187 (2006).  
123. Yan L, Womack B, Wotton D, Guo Y, Shyr Y, Dave U, Li C, Hiebert S, Brandt 
S, Hamid R. Tgif1 regulates quiescence and self-renewal of hematopoietic stem 
cells. Mol Cell Biol. 33;4824-4833 (2013).  
89
124. Carcalano G, Lee J, Kikly K, Ryan AM, Pitts-Meek S, Hultgren B, Wood WI, 
Moore MW. Neutrophil and B cell expansion in mice that lack the murine IL-8 
receptor homolog. Science. 265;682-684 (1994).  
125. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of 
neutrophil release from the bone marrow under basal and stress granulopoiesis 
conditions. Blood. 113;4711-4719 (2009).  
126. Zarbock A, Ley K. Mechanisms and consequences of neutrophil interaction with 
the endothelium. Am J Pathol. 172;1-7 (2008). 
127. McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the 
vascular wall. Cardiovasc Res. 107;331-339 (2015).  
128. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J. Intracellular 
pool of vascular endothelial growth factor in human neutrophils. Blood. 90;4153 (1997). 
129. Scapini P, Calzetti F, Cassatella MA. On the detection of neutrophil-derived 
vascular endothelial growth factor (VEGF). J Immunol Methods. 232;121 (1999).  
130. Cassatella MA. Neutrophil-derived proteins: selling cytokines by the pound. Adv 
Immunol. 1999.  
131. Sakaguchi H, Seki S, Tsubouchi H, Daikuhara Y, Niitani Y, Kobayashi K. 
Ultrastructural location of human hepatocyte growth factor in human liver. Hepatology. 
19;1157 (1994). 
132. McCourt M, Wang JH, Sookhai S, Redmond HP. Activated human neutrophils 
release hepatocyte growth factor/scatter factor. Eur J Surg Oncol. 27;396 (2001).  
133. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, Cassatella M, 
Noonan DM, Albini A. Neutrophils as a key cellular target for angiostatin: implications for 
regulation of angiogenesis and inflammation. FASEB J. 16;267 (2002).  
134. Scapini P, Morini M, Tecchio C, Minghello S, Di Carlo E, Tanghetti E, Albini A, 
Lowell C, Berton G, Noonan DM, Cassatella MA. CXCL1/macrophage inflammatory 
protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular 
endothelial growth factor-A. J Immunol. 172;5034-5040 (2004). 
135. Gong Y, Koh DR. Neutrophils promote inflammatory angiogenesis via release of 
preformed VEGF in an in vivo corneal model. Cell Tissue Res. 339;437-448 (2010).  
136. Espin-Palazon R, Stachura DL, Campbell CA, Garcia-Moreno D, Cid ND, Kim AD, 
Candel S, Meseguer J, Mulero V, Traver D. Proinflammatory signaling regulates 
hematopoietic stem cell emergence. Cell. 159;1070-1085 (2014).  
90
